INDEX TO VOLUME 183

Author Index

Abbed, K., 213
Abbott, S., 984
Abdel-Muhsin, A., 1535
Abdillahi, F., 89
Abraham, G. N., 995
Abraham, S. N., S51
Abrams, E. J., 539, 1541
Ackers, M.-L., 1701
Acosta, E., 715
Adams, D. R., 1023
Adams, G. J., 461
Adarna, B. C., 1494
Adcock, P., 1701
Adderson, E. E., 1694
Addiss, D. G., 1373
Adult and Adolescent Spectrum HIV Disease Project, 1409
Agadzi-Naqvi, A. K., 653
Agnew, K., 913
Aguiar, J., 303
Ahuja, S. K., 1574
Ahuja, S. S., 1574
AIDS Clinical Trials Group 373 Study Team, 715
AIDS Vaccine Evaluation Group 022 Protocol Team, 563
Albert, G., 697
Alberti, C., 1586
Alecrim, M. G., 1832
Ali, I. M., 1787
Allerberger, F., 670
Alonso, P. L., 1100, 1413
Alpers, M. P., 192
Alter, H. J., 359
Aly, A. A., 1694
Ammann, A., 539
Amundson, G., 1353
Anastos, K., 1130
Andersen, P., 175
Andersen, P. L., 1625
Anderson, G., 1526
Anderson, L. J., 16, 810
Anderson, R., 604
Anderson, S. A., 1000
Anderson, S. M., 8
Andrade, J. R. C., 762
Andreu, A., 485
Andrews, M.-M., 977
Angel, J. B., 546
Anton, P. A., 143
Antony, V. B., 1638
Aponte, J. J., 1413
Apple, R. J., 1554
Arend, S. M., 175
Arkin, S., 589
Armstrong, G. D., 435
Armstrong, G. L., 1295
Armstrong, W., 819
Arokiasamy, J. T., 810
Arrowood, M. J., 1373
Arya, S. C., 517
Ashbaugh, A. D., 943
Ashby, D., 546
Asmuth, D., 1336
Astemborski, J. A., 973
Atkins, G. J., 1395
August, M. J., 1281
Aung, H., 1801, 1805
Aura, J., 913
Awooda, A., 1825
Axon, A. T. R., 620
Babiker, H. A., 1535
Babinchak, T., 1682
Badley, A. D., 546
Baghdadi, A., 313
Bah, A., 1713
Bahrani-Mougeot, F. K., S21
Bailey, J. A., 960
Baillargeon, J., 125
Baird, J. K., 1653
Bakshi, S., 1445
Baldanti, F., 333
Ballon, G., 417
Ballou, W. R., Jr., S84, 640
Balsley, J., 1485
Bamberger, J. D., 707
Bamshad, M., 1574
Banatvala, N., 1063
Bang, D., 1180
Bar, M., 218
Barber, B. H., 503
Barbouche, R., 744
Barbuti, G., 1055
Baretton, G., 1187
Barnes, P. F., 478
Barousse, M., 277
Barreto, A., 1413
Barrett, T. J., 1063
Bartelds, A. I. M., 675
Barthold, S. W., 1781
Bartlett, J. A., 1522
Bartlett, L., 164
Bartolomé, R. M., 485
Basco, L. K., 1828
Battegay, M., 1425
Baughman, A., 1353
Baughn, R. E., 827
Baumgarten, G., 1617
Bausch, D. G., 1713
Bazin, C., 1539
Bean, N., 753
Beard, C. B., 819
Beierle, L. M., S81
Belec, L., 1328
Bell, B. P., 1273
Belle, S. H., 1112
Bellman, P. C., 571
Belshe, R. B., 1343
Bennuri, B., 1445
Berencsi, K., 1171
Berg, S., 36
Berger, E. A., 1592
Bergeron, M. G., 70
Bergeron, Y., 70
Berglund, P., 1395
Bergsten, G., S43
Berke, T., 681
Bern, C., 492
Bernstein, D. I., 59, 844
Berrey, M. M., 1466
Bertorelle, R., 814
Beschin, A., 1794
Besser, J., 1353
Besser, R. E., 907
Bewtra, C., 1547
Bhattacharjee, A. K., 1079
Bian, Z., 612
Biasio, L. R., 1819
Bibb, W. F., 1063
Biegel, D., 697
Bilé, C., 1405
Bilello, J. A., 1126
Billmann, L., 1138
Biron, K. K., 333
Bisgard, K. M., 1360
Bishop, R., 753
Bistoni, F., 51
Blackwell, J. M., 261, 1156
Blanche, S., 1565
Blankson, J. N., 657
Blanton, R. E., 960
Blazevic, V., 1000
Bloor, S., 143
Blum-Oehler, G., S17
Bock, A., 1574
Boeckh, M., 377
Bohnsack, J. F., 1694
Bolan, G., 1087
Bologna, R., 1574
Bonacini, M., 134
Bond, V. C., 138
Bönicke, L., 1161
Bonnez, W., 1485
Booher, S. L., 347
Borrow, R., 160
Bös, C., S12
Bosche, M., 36
Bosworth, B. T., 347
Bouchonnet, F., 1009
Bourne, N., 59
Bourreau, E., 953
Bouteille, B., 988
Bower, W. A., 1273
Bozeman, S., 23
Braffman, M., 1682
Brambilla, A., 1476
Brandl, M., 984
Brandt, C. M., 670
Braun, M., S12
Braun, V., S12
Bravo, F. J., 59
Bredt, B. M., 1399
Brenner, F. W., 753
Briles, D. E., 1501
Britt, W. J., 1547
Brock, I., 175
Brodard, V., 213
Brodie, S. J., 1466
Bronze, M. S., 65
Brooks, J., 1701
Broughton, K., 239
Brown, A. J. L., 1318
Brown, P., 192
Brown, R. C., 1678
Bruce, A. W., S77
Bruun, J. N., 1290
Brys, L., 1794
Buchbinder, S. P., 23, 1343
Buffet-Janvresse, C., 213
Buguet, A., 988
Bulterys, M., 539, 1541
Bungiro, R. D., Jr., 1380
Bunnell, J. E., 1431
Burk, R. D., 8
Burkhardt, B., 579
Burman, W., 819
Burnett, M. S., 226
Burns, D., 1130
Burns, J. L., 444
Burns, S., 1353
Burr, R., 1152
Burroughs, A. K., 835
Buseyne, F., 1565
Butera, S., 1023
Buti, M., 1277
Butters, T., S70
Butterworth, A. E., 960
Bwayo, J. J., 206, 503, 1017
Byrd, R., 687
Cabrera, L., 492
Cabrera, T., 1204
Cadoz, M., 1171
Cahoon-Young, B., 1087
Cainelli, F., 1428
Call, S. A., 401
Callea, F., 134
Camacho, M., 105
Cameron, D. W., 546
Campbell, J. V., 984
Campbell, L. A., 1368
Campbell, M., 1485
Cannon, D., 810

Cannon, M. J., 1304
Cappello, M., 1380
Cardenas, V., 1308
Cardesa, A., 1100
Carlino, U., 154, 1508
Carlone, G., 97
Carlton, J. M.-R., 1653
Carmagnat, M. V., 1586
Carnelli, V., 1819
Carosi, G., 134
Carr, A., 736
Carrera, P., 1476
Carter, J., 819
Cartwright, K., 160
Carvalho, F. A. A., 1646
Casadevall, A., 1093
Casimiro, S., 1413
Casseb, J., 1305
Cassiday, P. K., 1360
Castile, R., 444
Castillo, J., 503
Castro, G. A., 1646
Catano, G., 1574
Cate, T. R., 329
Cattelan, A. M., 417
Cavaillon, J.-M., 294
Celum, C. L., 23, 1343
Centre de Recherche Integré sur le VIH Bichat-Claude Bernard, 1009
Cervenáková, L., 192
Cespuglio, R., 988
Challener, R. C., 831
Chambers, D., 707
Chancerel, B., 857
Chandrasekaran, A., 1445
Chaouat, G., 1530
Charron, D., 1586
Chatterjee, A., 1547
Chavan, S., 1445
Checkley, W., 492
Cheletz, G., 880
Chen, M., 1395
Chen, N., 1543
Chen, R.-F., 850
Chen, Y.-H., 1071
Chêne, G., 1539
Cheng, Q., 1543
Chensue, S. W., 967
Cheon, S.-H., 1300
Chernoff, D., 589
Chernoff, M., 343
Chesney, M., 707
Chieco-Bianchi, L., 417, 814
Chiesi, A., 1290
Chiwakata, C. B., 1161
Cho, I., 1281
Chohan, B., 1017
Chong, M.-C., 850
Chougnet, C., 1260
Chow, A. W., 1739
Christie, C. D. C., 1360
Chun, T.-W., 1466
Cimaz, R., 1819
Clark, H. F., 1108
Clark, R. A., 1574
Clarke, M. J., 16
Clavel, F., 1009
Clemens, J. D., 1306, 1775
Cloud, G. A., 401
Coates, T. J., 707
Cochet, M., 857
Cockeran, R., 604
Coe, J. E., 185
Cohen, J., 640
Cohen, M., 1130
Cohen, S. S., 409
Cohn, L. A., 919
Coleman, R., 1254
Collaborative Protocol 020 Study Group, 392
Collier, A. C., 722, 1466, 1673
Collins, W. E., 1653
Colucci, M., 1055
Concia, E., 1428
Condra, J. H., 993
Connick, E., 555
Connolly, P., 1822
Conrad, J. T., 119
Coombs, R., 1466
Cooper, D. A., 736
Cooper, P. J., 1662
Coovadia, H. M., 653
Corey, L., 377, 555, 1343, 1466, 1669
Cornick, N. A., 347
Cot, M., 1530
Cotrina, M., 1277
Cotter, S. M., 1273
Couch, R. B., 329
Coulson, P. S., 1238
Courageot, J., 744
Courtenay, O., 1421
Courtois, P., 988
Coutsoudis, A., 653
Cox, W. I., 1171
Crabtree, J. E., 620
Crain, M. J., 1501
Crandall, K. A., 36
Crane, L., 819
Creasey, A. A., 1815
Cremer, E., 1152
Cron, S. G., 687
Crook, D. W., 239
Cross, A. S., 1079
Cummings, R. D., 1238
Cummins, J. E., Jr., 1204
Cunningham, M. W., 507
Cunningham, P. H., 736
Cunningham, S., 1732
Currier, J. S., 715
Curtis, S. J., 1426
Cutright, J. L., 277
Cutts, F., 532
Cytomegalovirus Retinitis and Viral Resistance Study Group, 333
Daar, E. S., 589
Da Costa, M., 383
Dagan, R., 880
Dale, D. C., 321
Dallaire, F., 70
Damian, R. T., 313
D'Angelo, E., 1819
Dankert, J., 675
Daoust, M., S21
D'Aquila, R. T., 715
da Rosa, A. P. A. T., 1431
da Silva, L. H. P., 1832
Daulouède, S., 988
Davey, R. T., Jr., 36
David, D., 730
Davis, C. L., 1669
Davis, J. L., 333
Davis, T. L., 125
Day, M. J., 1421
Dean, D., 1543
De Baetselier, P., 988, 1794
Deeks, J., 97
Deen, J., 1254
De Gruttola, V., 1455
Dehée, A., 857
DeHovitz, J., 1130
de Jonge, E., 1815
Dekkers, P. E. P., 1815
Delapenha, R. A., 392
Delavari, P., 78, 154, 425, 897, 1508
Delchambre, M., 640
Del Giudice, G., 1055
De Lorenzo, D., 633
Deloron, P., 1165, 1530
del Portillo, H. A., 1653
Delwart, E. L., 173
DeMars, L. R., 977
Demeter, L. M., 174, 1485
Deng, J.-H., 125
Dennis, V. A., 1221
Dentinger, C. M., 1273
De Rinaldis, P., 1055
De Rossi, A., 417, 814
Derouin, F., 1586
DeSimone, J., 1682
Désiré, N., 857
des Vignes, F., 773
Detrick, S. R., 1694
Deutch, L., 1678
Dewar, R. L., 36
Dezzutti, C. S., 1204
Dgedge, M., 1413
Dhanda, R., 1574
Dias, A. M. G., 762
Dias, L. B., 1431
Dietrich, M., 1161
Dietze, R., 1300
Dillberger, A., 1204
Dillon, H. K., 1825
DiRita, V. J., 1043
Di Vietro, M. L., 1108
Dixon, M. F., 620
Diz Dios, P., 355
Dobrindt, U., S17
Dockrell, D. H., 179
Doerschuk, C. M., 1638
Doherty, T., 1254
Dolan, M. J., 831, 1000, 1574
Dolfi, D. V., 1108
Donato, F., 134
Donfield, S., 589
Donnell, D., 23
Donnelly, J., 351
Donnenberg, M. S., S21
Dorigo-Zetsma, J. W., 675
Dornadula, G., 1682
Dorsey, G., 1417
Dou, S.-J., 633
Dougan, G., 261, 1156
Douglas, J. M., Jr., 23
Doukhan, L., 173
Dower, S. K., 89
Dowler, M. G., 640
Dragic, T., 1121
Drakeley, C., 1254
Drenning, S. D., 628
Drew, W. L., 1673
Dromer, F., 294
Drusano, G. L., 1126
Duan, R.-D., S47
Dubois, V., 213
Dubusky, L. M., 1273
Duc, C. M., 261, 1156
Duchin, J., 819
Dudbridge, F., 261, 1156
Duerr, A., 286
Duggirala, R., 1574
Duliege, A.-M., 1343
Dundon, W. G., 1055
Dunn, B. M., 579
Dunn, J. P., 333
Dunn, S. T., 507
Dunstan, S. J., 261, 1156
Dupont, B., 294, 730
Duran, C. M. G., 507
Durkin, M., 1822
Dussaix, E., 213
Dwek, R., S70
Dworkin, M. S., 1409
Dwyer, D. M., 1138
Dye, C., 1421
Dykes, C., 174
Eberl, M., 1238
Echols, R., 1126
Edwards, K. M., 1353, 1501
Edwards, L. J., 1522
Effler, P., 1152
Efstratiou, A., 239
Elie, C., 97
Ellerbrok, H., 130
Elliott, J., 143
Ellner, J. J., 779, 1300, 1801, 1805
Elmendorf, H. G., 119
Embree, J. E., 503
Emerson, J., 444
Emery, S., 680
Emery, S. R., 1017

Emery, V. C., 835
Emini, E. A., 993, 1318
Ender, P. T., 831
Engert, A., 321
Engleberg, N. C., 1043
Enomoto, N., 1195
Epstein, S. E., 226
Eriksen, T., 1625
Eron, J. J., 715, 1318
Erwin, J., 1518
Eschenbach, D. A., 913
Eshleman, S. H., 1732
Espinel, M., 1662
Espy, M. J., 179
Essex, M., 138
Esteban, R., 1277
Etzel, R., 1295
EuroSIDA Study Group, 1290
Evans, T. G., 1485
Evatt, B. L., 648
Ewer, K., 469
Excler, J. L., 1343
Fahey, J. L., 343
Falls, S., 1698
Falsey, A. R., 995
Fantini, J., 1311
Fantola, E., 1819
Farr, B. M., 1787
Farrar, Jeff, 984
Farrar, Jeremy, 261, 1156
Fauci, A., 1466
Favret, M., 134
Feinberg, J., 1285
Feldman, C., 604
Feng, S., 1781
Fenouillet, E., 744
Ferchal, F., 1539
Fernandes, A. P., 1646
Ferreira, L. A. M., 1646
Ferrenberg, J., 1669
Ferrer, B., 1100
Fessel, W. J., 392
Fex, C., 546
Fey, P. D., 1038
Fidel, P. L., Jr., 277
Fidock, D. A., 1653
Fievet, N., 1530
Findlow, J., 160
Finelli, L., 1601
Fischl, M., 1455
Fiscus, S. A., 1318, 1688
Fish, D., 773, 1781
Fisher, R. L., 571
Fitting, C., 294
Fitzgerald, C., 164
Flahart, R., 164
Fleeton, M. N., 1395
Flores, J., 23, 1343
Flores, R., 338
Florquin, S., 1143
Folks, T. M., 648, 1023
Fordham von Reyn, C., 478
Forman, M. S., 333
Fournier, S., 1586
Fowler, S., 1273
Fox, L., 343
Frame, P. T., 1722
Frame, R. D., 1285
Francis, C. W., 995
Frank, D. W., 1767
Frankel, G., 762
Franks, S., 796
Franses, K., 707
Franssila, R., 805
Fredricks, D. N., 1229
Freeman, W. R., 1399
Freet, K. J., 1781
Freitag, C., 1260
French Cryptococcosis Study Group, 294
Frendéus, B., S56, S61, S70
Frey, S., 1343
Fritsche, G., 1388
Froeschle, J., 1698
Frost, S. D. W., 1318
Fryauff, D. J., 1653
Fu, Y.-X., 633
Fuhrmann, S. R., 303
Fujimoto, J., 1767
Fujiyama, Y., 1540
Furukawa, Y., 1306
Gaastra, W., 897
Gachot, B., 730
Gaddam, A., 36
Gajdusek, D. C., 192
Galland, M. R., 478
Gallant, J. E., 657
Gamagami, R., 1318
Ganapamo, F., 1221
Ganz, T., S41
Gao, S.-J., 125
Garcez, L. M., 1421
García, E., 485
Garcia, Z., 857
Gargiulo, F., 134
Garin, J. F., 1586
Garringer, T., 1822
Garruto, R. M., 192
Gastl, G., 149
Gaydos, C. A., 226, 232
Gazzinelli, R. T., 1646
Geballe, A. P., 218
Gebhard, K., 555
Gebretsadik, N., S43
Geelen, S. P. M., 149
Genga, I., 1540
Gentsch, J. R., 1707
George, J., 1698
George, R., 239
Gerber, J. G., 715
Gerding, D. N., 1760
Gerlach, J. T., 1187
Gerson, G., 831
Gessain, A., 857
Ghezzi, S., 1476
Ghys, P. D., 1405
Gianotti, N., 1476
Gibson, R. L., 444
Gilbert, M., 907
Gilman, R. E., 1308
Gilman, R. H., 492
Giono-Cerezo, S., 1147
Girard, W. M., 478
Glad, S. M., 226
Glaser, K., 1079
Glass, A. G., 8
Glass, R. I., 1707
Glezen, W. P., 687
Goba, A., 1713
Godaly, G., S56, S61
Goedert, J. J., 539
Goh, L.-E., 736
Goldberg, J., 1822
Goldblatt, D., 160
Goldfarb, L. G., 192
Goluszko, P., 1526
Gomersall, C., 1360
Gomes, T. A. T., 762
Gómez-Olivé, X., 1413
Gómez-Román, J. J., 338
Gomperts, E., 589
Gönczöl, E., 1171
Gonzalez, E., 1574
González-Jiménez, I., 1832
González-Valencia, G., 1147
Goodenow, M. M., 579
Gooding, M. E., 1522
Gorse, G. J., 1343
Götz, F., 1038
Goudsmit, J., 1427
Gould, K., 1023
Gout, O., 857
Govindarajan, S., 134
Gozalo, A. S., 303
Gradus, M. S., 1373
Grant, R. M., 23
Graviss, E. A., 461
Gravitt, P., 8
Gravitt, P. E., 1554
Gray, L., 539
Green, J. H., 1063
Green, W. R., 977
Greenberg, A. E., 1405
Greenblatt, R. M., 383, 1130
Greene, J., 1380
Greene, K. D., 1063
Greenspan, J. S., 343
Greenwood, B., 97
Grekula, B., 1269
Grene, E., 409
Greten, T. F., 197
Grey, P., 736
Griffin, D. E., 498, 532
Griffin, P. M., 1063
Griffith, D. E., 478
Griffiths, D., 239
Griffiths, P. D., 835
Grigsby, D., 633
Gruener, N. H., 1187
Gryszowka, V., 1522
Guardia, J., 1277
Gubareva, L. V., 523
Guderian, R. H., 1662
Guenthner, P. C., 1204
Guerrero, M. L., 681
Guffanti, M., 1476
Guist'hau, O., 213
Gulick, R. M., 715, 1318, 1455
Gunsilius, E., 149
Günthard, H. F., 1318
Gunther, N. W., IV, S32
Guyer, D. M., S32
Guzman, H., 1431, 1437
Gyulai, Z., 1171
Haas, D. W., 392
Haase, A. T., 555, 1318
Haase, G., 670
Habib, R. E., 1343
Hablützel, M., 247
Haburchak, D., 138
Hack, C. E., 1815
Hacker, J., S17
Hager, S., 277
Hall, E. L., 1138
Hall, T., 640
Hall, W. J., 995
Hamilton, C. D., 1688
Hammer, S., 1455
Hammitt, L. L., 1694
Hammond, A. S., 928
Hance, A. J., 1009
Handsfield, H. H., 269
Hang, L., S56, S61
Hansen, G. R., 164
Hanson, D. L., 1409
Hansson, G. K., 612
Haque, R., 1787
Hara, T., 1
Hardwick, J., 1638
Harmsen, W. S., 179
Harris, C. E., 943
Harrison, C. J., 844, 1547
Harrison, L. H., 1138
Harro, C., 1343
Hart, A., 1526
Hassan-Walker, A. F., 835
Havlir, D. V., 555, 1318, 1455
Hayat, M., 620
Hayden, F. G., 523
Haynes, J. D., 303
Hazelwood, J. D., 1688
Hazenbos, W. L. W., 871
Heale, J.-P., 1214
Heath, A., 1043
Heaton, P. A., 1108
Hedlund, M., S47, S61
Hedman, K., 805
Heffernan, R., 773
Heijnen, M.-L. A., 675
Heilmann, C., 1038
Heisey, D. M., S81
Hellmann, N. S., 401
Hellwig, S. M. M., 871
Hemophilia Growth and Development Study, 589
Heneine, W., 648

Henning, K. J., 1138
Henry, K., 571
Henry, N. L., 512
Heppner, D. G., 640
Hernandez, M. T., 1087
Hertogs, K., 143
Hiatt, P., 444
Hida, N., 620
Hien, T. T., 261, 1156
Hildesheim, A., 8
Hilgartner, M. W., 589
Hill, A., 992
Hill, A. V. S., 469
Hirasawa, M., 823
Hirsch, C. S., 779, 1801, 1805
Hirsch, M. S., 722
Hirschel, B., 1833
Hirsilä, M., 1269
Hise, A. G., 1300
HIV Epidemiology Research Study Group, 286, 973
HIV-HCV Coinfection Study Group, 134
Ho, V. A., 261, 1156
Hodzic, E., 1781
Hoe, N. P., 633
Hoepelman, A. I. M., 149
Hoering, A., 722
Hoffman, S. L., 303
Hokynar, K., 805
Holland, C., 865
Holland, G. N., 1399
Holland, R., 670
Hollingshead, S. K., 1501
Hollingsworth, J., 1295
Holly, E. A., 383
Holman, R. C., 16
Hongvangthong, B., 789
Hooton, T. M., 343, 913
Hoots, W. K., 589
Hopkins, W. J., S81
Hossler, P. A., 819
Hott, J. W., 1638
Houghton, M., 1187
House, D., 1156
Howell, A. L., 977
Huang, L., 819
Huang, M.-L., 377, 1669
Huang, S.-H., 1071
Huang, W., 1455
Hübel, K., 321
Huggins, L. L., 329
Hull, R., S43
Hultgren, S. J., S36
Hundley, R. S., 1554
Hunt, J., 1353
Hunt, P., 1535
Hunt, W. C., 1554
Hunziker, L., 1425
Hurd, M. R., 1373
Hutchins, R. K., 1285
Hutson, A. D., 579
Hyde, T. B., 907
Icart, J., 213
Ichimura, H., 1540
Ieong, M.-C., 1152
Iga, M., 1031
Iglesias, I., 355
Ignacio, C. C., 1318
Ihara, K., 1
Ilstrup, D., 179
Imamichi, H., 36
Improvisi, L., 294
Ingolfsdottir, G., 253
Ingrand, D., 213
Inkathone, S., 789
Ioannidis, J. P. A., 539
Isaacs, R., 1318
Ismail, M. R., 1100
Ivanoff, B., 1306, 1707
Izumi, N., 1195
Jabs, D. A., 333
Jackson, A. M., 620
Jackson, E., 1023
Jackson, J. B., 343, 1732
Jackson, L. A., 1698
Jacobson, J. M., 343
Jacobson, L. P., 1130, 1304
Jacobson, M. A., 1399
Jacobson, S., 197
Jakobsen, H., 253, 1494
James, A. M., 1810
Jankelevich, S., 1116
Jankelow, D., 507
Janoff, E. N., 653
Janssen, R., 1023
Jardi, R., 1277
Jawara, M., 1254
Jaye, A., 928
Jenkins, F. J., 1304
Jenson, H. B., 125
Jerome, K. R., 1669
Jiang, M. K., 36
John, G. C., 206
Johnson, B. J. B., 1810
Johnson, D. R., 1135
Johnson, G., 1732
Johnson, J. A., 1138
Johnson, J. L., 779, 1805
Johnson, J. R., 78, 154, 425, 897, 1508
Johnson, M., 1290
Johnson, S., 1760
Johnson, V. A., 401, 1688
Joloba, M., 779
Joly, J. R., 628
Jonas, L., 1318
Jones, R. B., 1542
Jones, T. R., 303
Jones-Woodward, L., 453
Jong, A. Y., 1071
Jonsdottir, I., 253, 1494
Jouanne, C., 1565
Judson, F., 1343
Jülch, C., 1161
Jung, M.-C., 1187
Kageyama, S., 1540
Kahigwa, E., 1100
Kahn, J. O., 707
Kain, K. C., 789
Kaiser, L., 523
Kakimoto, K., 1540
Kalish, L. A., 1673
Kalish, R. A., 453
Kalou, M., 1405
Kamya, M. R., 1417
Kanangat, S., 65
Kaneshima, H., 498
Kang, S., 1678
Kaplan, E. L., 1135
Kaplan, M., 392, 919
Kaplan, R. F., 453
Kari, L., 1171
Karim, A., 1815
Kariuki, H. C., 960
Karpman, D., S47, S56
Kastenbauer, S., 1749
Kasuga, N., 1
Katz, J. M., 1000
Katz, M. H., 707
Kaufmann, G. R., 736
Kaul, S., 1126
Kauppila, J., 1269
Kaur, H., 810
Kawakami, K., 1
Kaye, P. M., 1421
Käyhty, H., 887
Kazanjian, P., 819
Kazatchkine, M. D., 1328
Keefer, M., 1343
Keitel, W. A., 329
Kennedy, P. E., 1592
Kenny, G. E., 269
Kesecioglu, J., 1815
Kessler, H., 392
Kestens, L., 1405
Kester, K. E., 640
Kharbanda, M., 1445
Khattab, A., 1165
Kilgore, P. E., 1775
Killmann, H., S12
Kilpi, T. M., 887
Kim, B. J., 1607
Kim, C. N., 1023
Kim, J., 164
Kim, K. S., 1071
Kim, Y., 1775
Kimpen, J. L. L., 149
Kimura, A., 1152
King, A. S., 928
King, C. H., 960
Kinney, S., 1248
Kirk, O., 1290
Kiyono, H., 823
Kjaergaard, K., S28
Klausner, J. D., 1087
Klein, M., 1343
Klein, M. R., 928
Klein, R. S., 286, 973
Klemm, P., S28
Klenerman, P., 835
Klinkert, M.-Q., 1165
Klion, A. D., 512
Knower, S., 1295
Knox, K., 239
Knuefermann, P., 1617
Kobayashi, N., 1540
Koblavi-Dème, S., 1405
Koblin, B., 23
Koch, N., 1311
Koedel, U., 1749
Koelle, D. M., 1130
Koenig, S., 1485
Kohler, S., 1822
Kolassa, J. E., 995
Komanduri, K. V., 1285
Konkel, M. E., 1607
Koram, K. A., 796
Korber, B. T., 539
Korfhagen, T. R., 943
Korkeila, M., 887
Kosanke, S., 507
Kotecka, B., 1543
Koup, R. A., 1678
Kowal, R. P., 1592
Kozel, T. R., 51
Kravcik, S., 546
Kreiss, J. K., 206, 1017
Kremsner, P. G., 113, 168, 1165
Krieger, J., 555, 1466
Krogstad, P., 1732
Kruglov, E., 1380
Kryger, J. V., S81
Krzych, U., 640
Ksiazek, T. G., 810
Kubota, R., 197
Kuhn, L., 653, 1541
Kuhr, C. S., 1669
Kulasegaram, R., 1518
Kum, W. W. S., 1739
Kumar, A., 546
Kumar, L., 1701
Kun, J., 1165
Kunin, C. M., S9
Kuo, C.-C., 1368
Kuritzkes, D. R., 715
Kurman, R. J., 8
Kuroda, M. J., 722
Kuskowski, M., 78, 897, 1508
Kwon, H. J., 1180
Labbé, A.-C., 789
Labriola, D. F., 392
Lafon, M.-E., 213
Laga, M., 1405
Lake, D., 97
Lal, A. A., 492
Lal, R. B., 1204
Lalezari, J. P., 1285
Lalvani, A., 469
Lamers, S. L., 579
Lammie, P. J., 1373
Landen, K., 1300

Landt, O., 130
Lane, H. C., 36, 680
Langermann, S., S84
Langermans, J. A. M., 1238
Langhorne, J., 1260
Lanh, M. N., 261, 1156
Larcher, C., 1388
Larder, B., 143
Laskus, T., 666
Launois, P., 953
Law, M., 512
Lazzarin, A., 1476
Lechner, F., 835
Lecossier, D., 1009
Lee, E.-S., 1180
Lee, H.-S., 192
Lee, M.-S., 1281
Lee, S. I., 1180
Lee, Sophia, 1732
Lee, Sungnack, 1180
Lee, Y.-J., 1775
Leib, S. L., 247
Leiberman, A., 880
Leibovitz, E., 880
Leigh, J. E., 277
Leisenring, W., 377
Leist, T. P., 197
Lell, B., 168
Lemesre, J. L., 988
Lemonnier, F. A., 857
LeMonte, A., 1822
Lemp, G. F., 1087
Letvin, N. L., 722
Leutenegger, C. M., 1781
Levi, M., 1815
Levine, A. M., 1130
Levine, P., 1295
Levitz, S. M., 935
Leyva-Cobián, F., 338
Li, C., 1260
Li, C.-C., 850
Li, X.-D., 1336
Liang, H., 303
Liao, Q., 571
Liaw, K.-L., 8
Lien, H. P., 1707
Liesenfeld, O., 1248
Liewehr, D. J., 409, 1000
Lifton, M. A., 722
Liles, W. C., 321
Liljeström, P., 1395
Limaye, A. P., 377, 1669
Limor, J., 492
Lin, S.-F., 850
Lin, T.-M., 1368
Lin, T.-Y., 850
Lindholt, J., 1625
Linke, G., 1373
Linke, M. J., 943
Little, S., 555
Liu, H., 1601
Liveris, D., 1810
Loeffler, J. M., 247
Long, N. T., 1707
Longhi, M. S., 1428
Looney, R. J., 995
Lortholary, O., 294
Lory, S., 919
Lovato, R., 1662
Lovell, R., 138
Lowenstein, C. J., 232
Lozano, M.-J., 338
Luan, L. T., 1707
Lucas, C., 303
Lukey, P. T., 928
Lundgren, J. D., 1290
Lütticken, R., 670
Luty, A. J. F., 168
Luu, T., 303
Luxemburger, C., 261, 1156
Luzze, H., 779, 1805
Lye, M. S., 810
Lynn, H., 589
Ma, Y., 865
Mabunda, S., 1413
MacDonald, K. S., 503
Mackall, C. L., 1116
Mac Kenzie, W. R., 1373
Mackinnon, M., 1535
MacLennan, J., 97
Mac Trubey, C., 409, 1000
Maddon, P. J., 1121
Madico, G. E., 226, 232
Magak, P., 960
Magder, L. S., 1295
Magenta, L., 1476
Magill, A. J., 303
Mahanty, S., 1713
Maher, N. H., 1825
Mainardi, M., 814
Makokha, E., 1540
Malaviya, R., S51
Malawista, S. E., 1631
Mamin, M., 1187
Mancero, T., 1662
Mandaliya, K., 1017
Mandrell, R., 984
Manegold, C., 1161
Manganiello, P. D., 977
Mangano, A., 1574
Manion, D. J., 392
Manjrekar, R., 164
Mann, D. L., 1617
Manos, M. M., 8
Maral, J., 730
Marcato, P., 435
Markee, J., 722
Markowitz, L. E., 1601
Marmor, M., 23, 1343
Marsh, C. L., 1669
Marshall, J. H., 1204
Martin, B. K., 333
Martin, J. N., 707
Martin, S., 160
Martínez, C., 355
Marumo, F., 1195
Maryland Emerging Infections Program, 1138
Masiero, S., 417
Massing, B., 1214
Mathews, A., 1426
Mathie, S. L., 1281
Mathoulin-Pélissier, S., 294
Matise, I., 347
Matlola, N. M., 604
Matrosovich, M. N., 523
Matson, D. O., 681
Matsuoka, M., 1031
Mattes, F. M., 835
Matthews, A., 648
Maubert, B., 1530
Maurice, C., 1405
May, J., 168
Mayanja-Kizza, H., 1801, 1805
Mayaux, M. J., 539
Mayer, K., 23, 286, 1343
Mayers, D., 1466
Mayon-White, R. T., 239
Mayor, A. G., 1413
Mbawuike, I. N., 687
Mbori-Ngacha, D. A., 206
Mbugua, G., 960
McAdam, K. P. W. J., 928
McBean, M., 596
McClelland, R. S., 1017
McCormack, F. X., 943
McCoy, K., 444
McCune, J. M., 1285, 1399
McCutchan, T. F., 1653
McDonald, A. C., 1373
McElrath, M. J., 722, 977
McFarland, W., 1087
McGhee, J. R., 368, 823
McGuinness, D., 796
McHugh, M., 779
McKinney, D. A., 640
McKirnan, D., 1343
McNamara, A. M., 1295
McNamara, J., 1343
McNamara, S., 444
Meddows-Taylor, S., 662
Meduri, G. U., 65
Mega, J., 823
Mehta, A., 469
Meibohm, A., 1318
Meier, A. S., 913
Mellors, J., 1318, 1455
Melnick, S., 1130
Mendelman, P. M., 1281
Mendez, J. C., 179
Menendez, C., 1100
Mensi, C., 1819
Meric, C., 1171
Merrigan, M. M., 1760
Meshnick, S. R., 819, 967
Mestecky, J., 368
Metcalf, J. A., 36
Meyer, C. G., 168
Michelson, S., 1171
Michiels, L., 143
Mickey, T., 1601
Middendorf, B., S17
Miller, A., 1043
Miller, E., 160, 239
Miller, R. L., 844
Milligan, P., 1254
Milone, V., 1819
Mintz, E., 1701
Miotti, P., 1130
Miquelis, R., 744
Mitchell, D. K., 681
Mitchell, T. J., 604
Mizokami, M., 359
Mobley, H. L. T., S32
Moch, J. K., 303
Mocroft, A., 1290
Mofenson, L. M., 539
Mohamed, A. S., 1328
Mohamed, F., 313
Mohammed, K. A., 1638
Mohle-Boetani, J., 984
Molina, J.-M., 1539, 1586
Molins-Pujol, A. M., 105
Molitor, F., 1087
Monari, C., 51
Monroe, S. S., 681
Montana (ANRS 091) Study Group, 1539
Montecalvo, M. A., 1810
Montecucco, C., 1055
Montemurro, P., 1055
Montgomery, R. R., 1631
Montoya, J. G., 1248
Monze, M., 532
Mooi, F. R., 871
Moon, H. W., 347
Moormann, A. M., 967
Morales-Montor, J., 313
Moret, H., 213
Morris, J. G., Jr., 1295
Morris, R., 160
Morrow, S., 1087
Morse, S., 1601
Moscicki, A.-B., 865
Moser, C. A., 1108
Moss, W. J., 532
Mounts, A. W., 810
Moussa, M., 1530
Moxon, E. R., 97, 239
Moynet, D., 988
Mubiru, F., 1801, 1805
Muchiri, E. M., 960
Mueller, B. U., 1116
Mueller, N., 1031
Mugerwa, R. D., 779
Mugyenyi, P., 779
Mühldorfer, I., S17
Müller, C. W., 130
Mulligan, M., 1343
Mulvey, G., 435
Mulvey, M. A., S36
Mummidi, S., 1574

Munk, M. E., 175
Muñoz, A., 1304
Muñoz, L., 1147
Muñoz, O., 1147
Murone, M., 1476
Murphy, E. L., 1673
Murphy, M., 1395
Murphy, R. L., 715
Murray, A. C., 897
Musey, L. K., 977
Musher, D. M., 827
Musser, J. M., 461, 633
Mwapasa, V., 967
Mwatha, A., 206
Myers, G., 1273
Myers, T., 277
Nachman, S., 1732
Nagai, M., 197
Nagashima, K. A., 1121
Nagayama, K., 1195
Nagelkerke, N. J. D., 503
Nagvenkar, P., 469
Nainan, O. V., 1273
Naït-Ighil, L., 730
Nakashima, K., 633
Nakata, M., 1152
Nalugwa, G., 1801, 1805
Namangala, B., 1794
Nannini, E. C., 679
Narum, D. L., 303
Nash, T. E., 119
Nasreen, N., 1638
Nasveld, P., 1543
Natarajan, V., 36
Nation, P. N., 435
National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group, 343
National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET), 1343
Navin, T. R., 1409
Ndinya-Achola, J. O., 206, 503, 1017
Nduati, R. W., 206
Near, K. A., 1260
Neaton, J. D., 680
Nelson, R. P., 1116
Neumann, A. U., 1678
Newell, M.-L., 539
Newhouse, E., 313
Newman, C., 138
Nguyen, B.-Y., 1116
Nguyen, H. H., 368
Nichols, J., 1336
Nicolle, L. E., S5
Nikkels, P. G. J., 149
Nilsson, Å., S47
Nino, D., 329
Nitsche, A., 130
Njenga, S., 503
Nkengasong, J. N., 1405
Nkrumah, F., 796
Noël, W., 1794
Nokta, M. A., 1336
Nolt, K. R., 973
Nomura, A., 1
Nomura, T., 1653
Nordin, J., 1353
Normark, S., 612
Norrby, S. R., S1
Norris, D., 571
Nosanchuk, J. D., 1093
Nowicki, B., S24, 1526
Nowicki, M., 666
Nowicki, S., S24, 1526
Nozaki, N., 1617
Nozza, S., 1476
Ntambi, L., 779
Nunnari, G., 1682
Nutman, T. B., 512, 1662
Nyame, A. K., 1238
Obaro, S., 97
O'Brien, D., 1485
O'Brien, S. J., 589
O'Bryan, T. T., 425, 1508
Ocampo, A., 355
Ocejo-Vinyals, J. G., 338
Ochieng, J. B., 1701
Ockenhouse, C. F., 640
O'Donnell, J. J., 1399
Offit, P. A., 1108
Ogg, G. S., 928
O'Hagan, D. T., 351
Ohga, S., 1
Ohmit, S. E., 286
Ohmura, M., 823
Okamoto, M., 1031
Okayama, A., 1031
Okello, C., 1540
Okwera, A., 779
Olsen, S. J., 164, 753
Olson, W. C., 1121
O'Mara, E., 1126
Ometto, L., 417, 814
Opal, S. M., 1079
Ordi, J., 1100
Osset, J., 485
Østergaard, L., 1625
Otake, S., 823
Otero, I., 355
Otten, R. A., 1023
Ottenhoff, T. H. M., 175
Ottinger, J. S., 1522
Ouellet, N., 70
Ouma, J. H., 960
Ovalle, R., 1093
Overbaugh, J., 206, 1017
Oyug, J., 503
Pahwa, S., 1445
Paigen, B., 226
Palaci, M., 1300
Palacín, A., 1100
Palardy, J. E., 1079
Palefsky, J. M., 383
Palensky, J., 640
Palumbo, P., 1732
Pan, X., 633
Pan, Y.-F., 1775
Pancholi, S., S21
Panos, G., 1290
Panteleeff, D., 206
Pape, G. R., 1187
Papini, E., 1055
Para, M. F., 1673
Parashar, U. D., 810
Parato, K. G., 546
Parejo, N. A., 1079
Parienti, J. J., 1539
Park, J.-K., 1775
Parker, S. E., 1395
Parkin, N. T., 1688
Parry, C., 1156
Pathan, A. A., 469
Patton, D. L., 913
Pauli, G., 130
Paulson, S. K., 1815
Pawelczyk, E., 1526
Paxton, W. A., 1678
Paya, C. V., 179
Peacock, C. S., 1156
Pedersen, L., 1625
Pelinka, L. R., 1694
Pellett, P. E., 1304
Pendle, S., 662
Perez, E. E., 579
Pérez-Pérez, G. I., 1147
Perinatal AIDS Collaborative Transmission Study, 1541
Perkins, D. J., 113
Permar, S. R., 532
Peters, B. S., 1518
Peters, C. J., 1713
Peters, P., 779, 1801, 1805
Petri, W. A., Jr., 1787
Petropoulos, C. J., 993, 1688
Peyser, B., 579
Peyton, C. L., 1554
Pezzino, G., 164
Pfister, H. W., 1749
Pham, S. V., 401
Phan, H. M., 827
Phares, J., 831
Philipp, M. T., 1221
Phillips, M., 1300
Phillips, R. E., 835
Phillips, T., 919
Phillips-Howard, P., 1701
Phuong, C. X. T., 261, 1156
Pickering, L. K., 681
Piedra, P. A., 687
Piesman, J., 773
Pietrella, D., 51
Pietrobon, P. J., 1698
Piketty, C., 1328
Pillai, D. R., 789
Pillay, A., 1601
Pillay, K., 653
Pincus, S., 1171
Pinder, M., 1254
Pinto, L. A., 409, 1000
Pique, C., 857
Pizzo, P. A., 1116
Platt, F., S70
Plotkin, S., 1171
Ploughman, L. M., 392
Plummer, F. A., 503
Poles, M. A., 143
Poli, G., 1476
Pollard, A. J., 1214
Pollard, R. B., 1336
Pomerantz, R. J., 1682
Pomphida, S., 789
Poore, J. A., 967
Porat, N., 880
Porter, D. D., 1426
Postlethwaite, A., 65
Pou, A., 1336
Pradinaud, R., 953
Press, C., 1248
Preston, S. L., 1126
Prévot, G., 953
Pridmore, A. C., 89
Priest, J. W., 1373
Primi, D., 359
Prince, G. A., 1426
Pringle, S. J., 1535
Pryor, J., 555
Public Health Laboratory Service and the Oxford Pneumococcal Surveillance Group, 239
Puhakka, T., 1269
Pullium, J. K., 1023
Pulvirenti, J. J., 343
Puoti, M., 134
Pursiainen, H., 887
Putzolu, V., 134
Quarles, J. M., 329
Quinn, T. C., 226, 232, 532
Quinnell, R. J., 1421
Rabian, C., 1586
Racca, S., 1476
Race, R. E., 185
Racine, S., 1767
Radkowski, M., 666
Radonić, A., 130
Ragni, M. V., 1112
Rajamani, S., 596
Rakela, J., 666
Ralston, M. L., 383
Ramakrishnan, G., 1787
Ramhadin, S., 503
Ramos, S. R. T. S., 762
Rampon, O., 814
Ramsey, B. W., 444
Ranford-Cartwright, L., 796
Raper, J. L., 401

Rappuoli, R., 1055, 1494
Rathore, D., 1653
Rau, H.-G., 1187
Raz, R., S74
REACH Project of the Adolescent Medicine HIV and AIDS Research Network, 865
Read, R. C., 89
Read, R. J., 435
Regnery, R., 831
Reichman, R. C., 1485
Reid, G., S77
Reilly, M., 1017
Reising, S. F., 1360
Reisner, B., 1526
Relman, D. A., 1229
Remington, J. S., 1248
Renwick, N., 1427
Reporter, R., 984
Revadigar, N. S., 1767
Rhodes, G., 1395
Ribeiro, F. C., 1300
Rich, J. D., 973
Richardson, B. A., 206
Richardson, J., 819
Richman, D. D., 555, 1318, 1455
Richmond, P., 160
Riggs, T., 164
Righetti, E., 417
Riley, E. M., 796
Ringer, R., 247
Ringwald, P., 1828
Rissing, J. P., 138
Rivera, C., 1043
Rivera-Amill, V., 1607
Rivière, Y., 1565
Roberts, J., 492
Roberts, N. E., 1360
Roberts, S., 507
Robinson, D. A., 1501
Robinson, P. A., 620
Rochford, R. A., 967
Roden, M., 518
Rodrigues, C., 469
Rodríguez, F., 1277
Roels, T. H., 753
Røge, B., 1290
Roilides, E., 518
Roland, M. E., 707
Rollin, P. E., 1713
Romagné, F., 1565
Roman, J., 1682
Rompalo, A., 286
Roord, J. J., 1143
Roosevelt, G. E., 16
Rosa, A. C. P., 762
Rosales, G. V., 648
Rose, R. C., 1485
Rose, S. L., 579
Rosenfeld, M., 444
Rosenfeld, M. E., 1368
Rosenfield, S. I., 1121
Rosenthal, P. J., 1417
Ross, L. L., 571
Ross, M. J., 185
Roth, W., 138
Rothstein, N. M., 232
Rouzioux, C., 1565
Rowe, T., 1000
Roy-Burman, A., 1767
RTS,S Malaria Vaccine Evaluation Group, 640
Rubanowice, D., 1698
Ruffault, A., 213
Ruga, E., 814
Ruiz, J., 1087
Ruiz, N. M., 392
Ruiz-Palacios, G., 681
Rupert, S. W. M., 149
Rupp, M. E., 1038
Russell, B., 1543
Russo, T. A., 154, 1508
Ruuskanen, O., 1269
Ryon, J. J., 532
Saag, M. S., 401
Sabath, D. E., 722
Sabin, C. A., 1518
Sack, D. A., 1306
Sack, R. B., 1787
Sadoff, J., 1308
Saeland, E., 253
Sahly, H. M. E., 461
Saito, M., 823
Salehi, E. D. P., 1273
Salge, S., S17
Sambol, S. P., 1760
Samten, B., 478
Samuel, J. E., 347
Samuelsson, M., S43
Sánchez, F., 1277
Sanchez, J., 1308
Sánchez-Velasco, P., 338
Sanden, G. N., 1360
Sanders, K. L., 1638
Sanders, L. L., 1522
Sandoval, C., 1662
Sandstrom, P., 648
Sangli, C., 1281
Santiago, H. C., 1646
Santos, G., 351
Sarwari, A. R., 1295
Sato, C., 1195
Saul, J., 1518
Savel, R. H., 1767
Sawa, T., 1767
Schaberg, D., 65
Schacker, T., 555, 1466
Schaeffer, A. J., S66
Schaufele, R. L., 518
Schembri, M. A., S28
Schennach, H., 1388
Schiffman, M., 8
Schilling, J. D., S36
Schirren, C. A., 1187
Schito, M., 1260, 1592
Schleif, W. A., 993, 1318
Schleiss, M. R., 59
Schmidt, D. K., 1285
Schmitz, J. E., 722
Schmutzhard, E., 149
Schneck, J. P., 197
Schneider, P., 1009
Schnittman, S., 1126
Schnizlein-Bick, C., 1822
Scholliers, A., 143
Schooley, R. T., 555
Schrier, R., 1399
Schuchat, A., 1138
Schulz, D., 1494
Schulz, T., 1427
Schulze, T. L., 773
Schuman, P., 286, 973
Schwartz, I., 1810
Schwartz, M. A., 269
Schwartz, S. B., 907
Scott, D. R., 8
Scott-Algara, D., 1565
Seekins, D., 392
Seiler, P., 1425
Sein, T., 518
Self, S., 1343, 1466
Selvarangan, R., S24
Semeraro, N., 1055
Sen, L., 1574
Serchuck, L., 1116
Seshu, J., 1607
Seth, A., 722
Sevin, A., 722
Shaefer, M. S., 571
Shams, H., 478
Shanley, J. A., 697
Shanley, J. D., 697
Shanmugam, V., 648
Shannon-Lowe, C., 218
Shapiro, D. E., 539
Shapiro, R. L., 1701
Shastri, J. S., 469
Shaw, M.-A., 1421
Shay, D. K., 16
Shea, T., 1466
Shearer, G. M., 409, 1000, 1260
Sheppard, H. W., 23, 1343
Sher, A., 1260, 1592
Sherman, M. E., 8
Shih, J. W.-K., 359
Shikuma, C., 343
Shimoyama, T., 620
Shin, J.-S., S51
Shivaprakash, M., 993
Shor, A., 1428
Siegert, W., 130
Sigurdardottir, S. T., 253
Siliciano, R. F., 657
Sim, B. K. L., 303
Simard, M., 70
Simell, B., 887
Simonis, T. B., 409
Simpson, D., 1214
Singer, S. M., 119
Singh, A., 1417
Sivasubramanian, N., 1617
Six, H. R., 329
Sjöström, K. E., 269
Sleasman, J. W., 579, 1116
Sleeman, K., 239
Slutsker, L., 753, 1152, 1701
Smeaton, L. M., 715
Smith, A. L., 444, 919
Smith, D., 736
Smith, D. K., 973, 1023
Smith, S., 1116
Smith, S. M., 928
Smith, T. F., 179
Smulian, A. G., 1722
Snyder, S., 715
Sobel, J. D., 277, 286
Sohn, S., 1180
Soini, H., 461
Sokurenko, E. V., S28
Soldini, L., 1476
Soler, M., 105
Sommadossi, J.-P., 715
Sonder, A., 164
Song, H.-Y., 1300
Songok, E. M., 1540
Soo-Hoo, Y., 523
Sørensen, H. T., 1625
Sørensen, T. E., 1625
Soucie, J. M., 648
Speert, D. P., 1214
Spellerberg, B., 670
Spinetti, A., 134
Spritzler, J., 343
Squires, K., 1455
Stablein, D., 1343
Stafford, K. C., III, 773
Staley, J., 1543
Stamm, W. E., S1, 1543
Stapleton, A., 913, 1508
Starr, S., 1171
Steeghs, L., 89
Steel, H. C., 604
Steele, P., 943
Steere, A. C., 453
Steinberg, S. M., 409, 1116
Steiner, B., 1601
Stell, A. L., 78, 154, 897
Stensland, L., 377
Stentz, F., 65
Stephens, H. A., 261
Stern, J., 1682
Stevens, C., 1343
St. Louis, M. E., 1601
Stockhammer, G., 149
Stokes, R. W., 1214
Stothard, D. R., 1542
Stout, J. E., 628
Strebel, P., 1353, 1360
Stuver, S., 1031
Su, X.-z., 1653

Subauste, C. S., 1722
Sulaiman, I., 492
Sun, E., 546
Surewicz, K., 1805
Sutherland, C., 1254
Sutton, M. Y., 1601
Suzich, J. A., 1485
Suzuki, K., 736
Svanborg, C., S43, S47, S56, S61, S70
Svensson, M., S47, S70
Swanson, B. L., 1767
Swerdlow, D. L., 164
Switzer, W. M., 648
Swoboda, R. K., 277
Tachibana, N., 1031
Tafuri, W. L., 1646
Takada, H., 1
Takada, K., 823
Takahashi, I., 823
Takahashi, S., 1694
Takahata, Y., 1
Takeda, Y., 823
Talkington, D. F., 907
Tamalet, C., 1311
Tambussi, G., 1476
Tami, G., 1530
Tanaka, T., 1
Tanaka, Y., 359
Tang, J. K., 1760
Targett, G., 1254
Täuber, M. G., 247
Tauxe, R. V., 753
Tavares, C. A. P., 1646
Taylor, D. N., 1308
Taylor, E., 453
Taylor, S. E., 831
Teeter, L., 461
Teglas, J. P., 539
Terebuh, P., 779
Tesh, R. B., 1431, 1437
Tetteh, K., 796
Thacker, W. L., 907
Thanh, N. T. H., 1707
Theron, A. J., 604
Thèze, J., 730
Thiongo, F. W., 960
Thomas, A. W., 1238
Thomas, D. L., 973
Thomas, F., 1328
Thomas, R. L., 1713
Thomasch, J. R., 1522
Thompson, D. A. D., 1121
Thompson, J., 277
Thorén, P., 612
Tiemessen, C. T., 662
Tivoli, N., 1311
Tkachuk, A. N., 967
Tognazzo, S., 814
Tolley, E., 65
Tolson, J. M., 401
Tomai, M. A., 844
Tomita, T., 620
Toossi, Z., 779, 1801, 1805
Tornieporth, N., 640
Torres, J., 1147
Torriani, F. J., 1399
Tortevoye, P., 857
Totten, P. A., 269
Tourres, C., 1311
Trabulsi, L. R., 762
Trach, D. D., 1707
Traoré-Ettiègne, V., 1405
Trivett, M. T., 409
Tsang, A., 1214
Tsubouchi, H., 1031
Tung, R., 715
Tuomaala, K., 1269
Udwadia, Z., 469
Uehling, D. T., S81
Ugozzoli, M., 351
Umemura, T., 359
Unnasch, T. R., 1825
Ureta-Vidal, A., 857
Urvil, P., 1526
Vaara, M., 633
Valentine, F., 1318
Vallanti, G., 1476
Vallejo, J. G., 1617
Valsamakis, A., 498
van der Flier, M., 149
Vander Helm, K., 435
van der Ley, P., 89
van der Nat, H., 675
van der Poll, T., 1143, 1815
van der Vlist, G. J., 149
van Deventer, S. J. H., 1143, 1815
van de Winkel, J. G. J., 871
van Diemen–Steenvoorde, R. A. A. M., 149
Vanella, M., 1682
van Furth, A. M., 1143
van Ginkel, F. W., 368
Vanham, G., 1801
Vanhems, P., 1833
Van Horn, R. D., 1638
Vanisaveth, V., 789
Vankayalapati, R., 478
Van Man, N., 1707
van Oirschot, H. F. L. M., 871
van Spriel, A. B., 871
Van Trang, N., 1707
Van Tu, P., 1707
Vargas Cuero, A. L., 835
Vasconcelos, P. F. C., 1431
Vazquez, J. A., 286
Vecchiarelli, A., 51
Veglia, F., 1476
Vekemans, J., 928
Vento, S., 1428
Ventura, P. J., 1100
Venzon, D. J., 1000
Verdon, R., 1539
Vermund, S. H., 865, 1825
Vervenne, R. A., 1238
Vetter, N., 1290
Viard, J.-P., 1290
Vicenzi, E., 1476
Vieira, M. A. M., 762
Vieira, P.-P., 1832
Vietnam Rotavirus Surveillance Network, 1707
Vila, L., 105
Vincendeau, P., 988
Vingerhoets, J., 143
Vinhas, S., 1300
Viral Activation Transfusion Study Group, 1673
Viswanathan, M. N., 1285
Vonk, G. J. H., 149
von Seidlein, L., 1254
Voss, G., 640
Vu, H. L., 368
Vuopio-Varkila, J., 633
Waase, I., 1161
Wacholder, S., 8
Wachtler, C., S61
Wagner, G. E., 796
Wahlquist, S., 1701
Waight, P., 239
Wain, J., 261, 1156
Waites, K. B., 1501
Waiyaki, P., 1701
Wajja, A., 1801, 1805
Wallace, R. J., 571
Wallace, R. J., Jr., 478
Walliker, D., 1535
Wallis, R. S., 1300
Walraven, G., 1254
Walsh, E. E., 995
Walsh, T. J., 518
Walter, J. E., 681
Walzer, P. D., 943
Wan, Z.-S., 1071
Wang, C. C., 1017
Wang, C.-L., 850
Wang, L.-F., 666
Wang, R. Y. H., 359
Wang, X.-M., 1631
Wang, X.-P., 125
Wang, Y.-G., 1732
Wantman, M., 1732
Warren, H. S., 1079
Watanabe, H., 1195
Watanabe, M., 1195
Watt, J. P., 907
Wattigney, W., 1353, 1360
Weber, A., 919
Weber, S. M., 935
Wei, L.-J., 1732
Weinberg, D. V., 333
Weinberg, J. B., 113
Weinhold, K. J., 1343, 1522
Weiss, G., 1388
Weiss, J. B., 269
Weiss, L., 1328
Wellems, T. E., 1653
Wellons, M. F., 1522
Wells, J., 687
Wells, J. G., 1063, 1701
Welsh, D. A., 1825
Werner, S. B., 984
Wessendarp, M., 1722
Westfall, A. O., 401
Weverling, G. J., 1427
Whalen, C., 1801, 1805
Wheat, L. J., 1822
Wheeler, C. M., 1554
Wheeler, J. G., 796
White, H. D., 977
White, W. I., 1485
Whiting, A. A., 1694
Whitsett, J. A., 943
Whittam, T. S., 154
Whittington, W. L. H., 269
Wiener-Kronish, J. P., 1767
Wiktor, S. Z., 1405
Wilbrink, B., 675
Wilfert, C. M., 539
Wilkinson, J., 666
Wilkinson, K. A., 469
Williams, K., 1574
Wilson, J. A., 179
Wilson, R. A., 1238
Winkler, C. A., 589
Winkler, F., 1749
Wira, C. R., 977
Wittes, J., 640
Wizel, B., 478
Wiznia, A., 1732
Wohl, D. A., 343
Wolf, K., 1425
Wolf, N. A., 277
Wolinsky, S. M., 1678
Womack, C., 138
Wong, J. K., 555, 1318
Wong, W.-Y., 589
Wood, L. V., 1116
Woods, C. R., 1688
Woody, G., 1343
Wootton, J. C., 1653
Workman, K., 453
Wormser, G. P., 1810
Worzfeld, T., 1187
Wright, P., 1343
Wu, M., 1801, 1805
Wullt, B., S43
Wyllie, D. H., 89
Xiao, L., 492
Xiao, S.-Y., 1431, 1437
Xu, Z.-Y., 1775
Ya, L. K., 1405
Yahi, N., 1311
Yamaguchi, K., 1031
Yamamoto, M., 823
Yan, Z.-Q., 612
Yanai, F., 1
Yang, H. H., 1775
Yang, K. D., 850
Yang, L. H., 1775
Yang, M.-Y., 850
Yarchoan, R., 1116
Yeaman, G. R., 977
Yeh, I.-T., 125
Yeo, A. E. T., 359

Yim, D., 444
Young, M. A., 1130
Young Women's Survey Team, 1087
Yu, O., 1698
Yu, V. L., 628
Zachoval, R., 1187
Zahradnik, J., 1171
Zalis, M. G., 1832
Zaltron, S., 134
Zanchetta, M., 417, 814
Zanetti, A. R., 1819
Zaunders, J. J., 736
Zeichner, S. L., 1116
Zell, E. R., 907
Zembrowski, E., 1373
Zhang, H., 1431, 1437, 1682
Zhang, Y.-J., 125
Zhang, Z.-Q., 555, 1318
Zhao, M., 1554
Zhong, K., 789
Ziegler, T., 1269
Ziermann, R., 993
Zinkernagel, R. M., 1425
Zwerski, S., 1116
Zwijnenburg, P. J. G., 1143

Subject Index

Abacavir, for human immunodeficiency virus infection, in triple combination, 571
Abscess, breast, mother-to-child human immunodeficiency virus transmission and, 206
Acquired immunodeficiency syndrome (*see* Human immunodeficiency virus infection [type 1 or unspecified])
Active transport, in *Escherichia coli* antibiotic uptake, S2
Adherence
  Escherichia coli, nonenteropathogenic, 762
  uropathogens, vaginal *Lactobacillus* inhibition, 485
Adherence lectin, antibodies to, in amebiasis, 1787
Adhesins
  Escherichia coli, in urinary tract infections, S24, S28, 1526
  Escherichia coli O18:K1:H7, in cystitis vs. neonatal meningitis, 425
  Staphylococcus epidermidis, in catheter infection pathogenesis, rat model, 1038
Adjuvants, for vaccination, *Escherichia coli,* mouse and pig models, 351
Adrenal gland, necrosis, in yellow fever, hamster model, 1437
Adrenocorticotropic hormone, in *Schistosoma mansoni* infection, baboon and mouse models, 313
African trypanosomiasis, resistance to, mouse model, 1794
Age, vs. CD4 T cell response, to highly active antiretroviral therapy for human immunodeficiency virus infection, 1290
AIDS (*see* Human immunodeficiency virus infection [type 1 or unspecified])
Albomycin, uptake, by *Escherichia coli* outer membrane channels, S12
Alkalinization, *Cryptococcus neoformans* phagolysome, chloroquine in, 935
Amblyomma americanum, in *Borrelia lonestari* transmission, 1810
Amebiasis, immune response, 1787
Amoxicillin/clavulanate
  resistance to, 880
  for tuberculosis, whole-blood bactericidal assay, 1300
Ampicillin, resistance to, *Escherichia coli,* 1526
Amplification phylotyping, *Escherichia coli* O18:K1:H7, in cystitis vs. neonatal meningitis, 425
Amprenavir, for human immunodeficiency virus infection
  combination therapy after, 715
  steady-state trough concentration:inhibitory concentration ratios in, 992, 993
Amyloid A, in influenza, in elderly persons, 995
Amyloid P, in scrapie, mouse model, 185
Ancylostoma ceylanicum, vaccination, hamster model, 1380
Anemia
  Cooley, *Haemophilus influenzae* vaccination in, 1819
  hemolytic, in hemolytic uremic syndrome, 1063
  in malaria, protection against, vs. human leukocyte antigen type, 168
Aneurysm, aortic, *Chlamydia pneumoniae* infection and, antibiotic effects on, 1625
Angina pectoris, *Chlamydia pneumoniae* infection and, antibiotic effects on, 1625
Animal models
  African trypanosomiasis resistance, mouse, 1794
  atherosclerosis pathogenesis, mouse, 226, 232
Behçet's disease pathogenesis, mouse, 1180
Bordetella pertussis clearance, mouse, 871
Borrelia burgdorferi pathogenesis, monkey, 1221
Clostridium difficile virulence factors, hamster, 1760
cryptococcosis treatment, mouse, 1093
cytomegalovirus infection
  mouse, 697
  vaccination for, guinea pig, 59, 1547
ehrlichiosis transmission, mouse, 773
endotoxic shock, mouse, 1617
enterohemorrhagic *Escherichia coli* vaccination with Shiga toxin 2 B subunit, rabbit, 435
Escherichia coli infection
  pathophysiology, mouse, 612
  Shiga toxin antibody in, pig, 347
  urinary tract, phylogeny and virulence, dog, 897
  vaccination, genetically detoxified mucosal adjuvant with, mouse and pig, 351
Escherichia coli J5 lipopolysaccharide/group B meningococcal outer membrane protein complex vaccination, sepsis, rabbit, 1079
Giardia lamblia variant-specific surface proteins, mouse, 119
herpes simplex virus infection, genital, treatment, guinea pig, 844
histoplasmosis reactivation, mouse, 1823
hookworm disease vaccination, hamster, 1380
human granulocytic ehrlichiosis, mouse, 1781
human immunodeficiency virus transmission, macaque, 1023
inflammatory response in scrapie, mouse, 185
influenza A virus heterosubtypic immunity, mouse, 368
leishmaniasis treatment, mouse, 1646
Lyme disease
  pathogenesis
    monkey, 1221
    mouse, 1631
  transmission, mouse, 773
malaria in human immunodeficiency virus infection, mouse, 1260
measles vaccine thymus damage, mouse, 498
microbial-induced proviral expression inhibition, mouse, 1592
nitric oxide synthases in bacterial meningitis, mouse, 1749
Plasmodium falciparum vaccination, monkey, 303
pneumococcal infection
  bacteremia protection, mouse, 827
  meningitis
    free-radical scavengers in, rat, 247
    pathophysiology, mouse, 1143
  pneumonia, mouse, 70
  vaccination
    mouse, 1494
    serotypes 6A and 6B, mouse, 253
Pneumocystis carinii infection susceptibility, mouse, 943
Pseudomonas aeruginosa infection in cystic fibrosis, 919
respiratory syncytial virus treatment, cotton rat, 1425
RNA vaccines, mouse, 1395
rotavirus infection, mouse, 1108
schistosomiasis
  hypothalamic-pituitary-adrenal axis hormones in, baboon and mouse, 313
  vaccination, chimpanzee, 1238
shock, nitric oxide scavenger treatment, rat, 105
Staphylococcus epidermidis catheter infection, rat, 1038
streptococci group A virulence factors, mouse, 1043
Streptococcus mutans vaccination, mouse, 823

toxic shock syndrome, mouse, 1739
urinary tract infections
bacterial pili, rodent, S36
glycosphingolipid inhibition, mouse model, S70
interleukin-8 receptor deficiency, mouse, S56
secreted proteins in, mouse, S32
vaccination, monkey and mouse, S81
visceral leishmaniasis, dog, 1421
yellow fever, hamster, 1431, 1437
Antibiotics *(see also specific antibiotics and diseases)*
failure to prescribe in Lyme disease, long-term impact, 453
prior exposure to, *Campylobacter jejuni* infection and, 1152
resistance to (*see* Drug resistance)
uptake, *Escherichia coli* outer membrane channels, S12
Antibody(ies)
glycans, in schistosomiasis vaccine response, chimpanzee model, 1238
glycoprotein B, in cytomegalovirus modification, guinea pig model, 1547
human immunodeficiency virus, human leukocyte antigens and, 409, 503
lectin, in amebiasis, 1787
monoclonal, toxic shock syndrome toxin–1, mouse model, 1739
neutralizing
in enterovirus 71 infection, in pediatric patients, 850
in human immunodeficiency virus vaccination, 563
parainfluenza virus type 3, in young infants, 1281
pneumococcal, in pneumococcal colonization, 887
pneumolysin, in pneumococcal bacteremia, mouse model, 827
Shiga toxin, in *Escherichia coli* infection, pig model, 347
Antigenic variation, in *Giardia lamblia* surface proteins, mouse model, 119
Antioxidants, in pneumococcal meningitis, rat model, 247
Antiretroviral agents *(see* Highly active antiretroviral therapy; *specific agents)*
Antitoxin, diphtheria, in subpotent diphtheria-tetanus toxoids administration, 1698
Anus, human papillomavirus infection, in human immunodeficiency virus–positive and high-risk women, 383
Aortic aneurysms, *Chlamydia pneumoniae* infection and, antibiotic effects on, 1625
Aphthous ulcers, in human immunodeficiency virus infection, thalidomide for, 343
Apoptosis
hippocampal, effects of free-radical scavengers on, in pneumococcal meningitis, rat model, 247
T cells, in tuberculosis, 779
Artesunate, for *Plasmodium falciparum* malaria, 1254
Arthritis, in Lyme disease, long-term evaluation, 453
Aspergillosis, invasive, interleukin-10 levels in, 517
Astrovirus, diarrhea, epidemiology, Mexico, 681
Atherosclerosis
exacerbation, in influenza, in elderly persons, 995
pathogenesis
Chlamydia pneumoniae in, 1368, 1625
infectious agents in, 1428
mouse model, 226, 232
Atovaquone, *Pneumocystis carinii* cytochrome b mutations and, 819
Autoimmune disorders, Lyme disease, monkey model, 1221
Autolysin, *Staphylococcus epidermidis,* in catheter infection pathogenesis, rat model, 1038
Autoreactive cells, expansion in Lyme disease, monkey model, 1221
Azithromycin
for *Chlamydia pneumoniae* infection, atherosclerosis development and, mouse model, 232
prophylactic, for *Mycoplasma pneumoniae* outbreak, 907
resistance to, 880

Bacteremia
pneumococcal, pneumolysin antibody protection in, mouse model, 827
Staphylococcus epidermidis, catheter related, pathogenesis, rat model, 1038
streptococcal group A, streptococcal inhibitor of complement variants in, 633
streptococcal group B, in nursing homes, Maryland, 1138
Bacterial vaginosis
cervical ectopy related to, in adolescent girls, 865
treatment, human immunodeficiency virus shedding and, 1017
Bactericidal assay, for *Mycobacterium tuberculosis,* in drug efficacy monitoring, 1300
Bartonella, coronary artery disease and, 831
B cells, in heterotypic immune response to influenza A virus, mouse model, 368
Behçet's disease, pathogenesis, mouse model, 1180
Bell's palsy, in Lyme disease, long-term evaluation, 453
BK virus, nephropathy, in kidney transplantation, 1669
Bladder infections (*see* Cystitis)
Blood-brain barrier
disruption, in meningitis, 149
permeability, to pneumococci, nitric oxide synthase in, mouse model, 1749
Blood pressure
high, septicemia with, hospitalization rate due to, in elderly persons, 596
in systemic *Escherichia coli* infection, mouse model, 612
Bloodstream infections (*see* Bacteremia)
Blood transfusions (*see* Transfusions)
BMS-232632, for human immunodeficiency virus infection, pharmacodynamics, 1126
Bone marrow
pathology, in ehrlichiosis, mouse model, 1781
transplantation, human herpesvirus 6A detection after, 130
Bordetella pertussis
clearance, mechanisms, mouse model, 871
infection, epidemiology
adolescents and adults in Minnesota, 1353
Cincinnati, 1360
Borrelia lonestari, infection, from *Amblyomma americanum* bite, 1810
Borreliosis (*see* Lyme disease)
Brain (*see also* Encephalitis; Encephalopathy; Meningitis)
endothelial invasion, *Escherichia coli* O18:K1:H7, in cystitis vs. neonatal meningitis, 425
free-radical scavenger effects on, in pneumococcal meningitis, rat model, 247
pathology, in ehrlichiosis, mouse model, 1781
spongiform encephalopathy, inflammatory response in, mouse model, 185
Brain microvascular endothelial cell invasion gene, *Escherichia coli,* 1071
Breast, infections, human immunodeficiency virus transmission and, mother-to-child, 206
Breast-feeding, human immunodeficiency virus transmission in, 206
Bronchiolitis, respiratory syncytial virus, mortality, United States (1979–1997), 16
Bronchitis, *Pseudomonas aeruginosa,* in cystic fibrosis, mouse model, 919

Bronchoalveolar lavage fluid, *Pseudomonas aeruginosa* detection in, in cystic fibrosis, longitudinal study, 444
N-Butyldeoxynojirimycin, for urinary tract infection prevention, mouse model, S70

Calcium, neutrophil permeability to, pneumolysin effects on, 604
Campylobacter jejuni
infection, epidemiology, in food handling, 164
virulence factors, invasion antigens, 1607
Canarypox, in vaccine preparation
cytomegalovirus, 1171
human immunodeficiency virus, 563, 1343
Cancer, cervical, human papillomavirus type persistence and, 8
Candida, colonization, in human immunodeficiency virus infection, 355
Candida albicans, complicated urinary tract infections, S5
Candidiasis, in human immunodeficiency virus infection
cellular immune response in, 277
drug-resistance evolution in, 286
vaginal, virus shedding and, 1017
2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide, for shock, rat model, 105
Carditis
in Lyme disease, mouse model, 1631
rheumatic, pathogenesis, 507
Carriage (*see* Colonization)
Caspase-1, in interleukin-18 expression, in *Helicobacter pylori* infection, 620
Catheter-related infections
urinary, S1
vascular, *Staphylococcus epidermidis,* pathogenesis, rat model, 1038
CD4 molecule (*see* T cells, CD4)
CD40 ligand, defective signaling, in human immunodeficiency virus infection, 1722
CD8 molecule (*see* T cells, CD8)
CD14 molecule, in *Pseudomonas aeruginosa* phagocytosis, 1214
CD28 molecule, antiretroviral therapy effects on, 546
CD88 molecule, in human immunodeficiency virus infection, with tuberculosis, 662
Cellular immune response (*see also* Cytokines; T cells)
canarypox vaccine for human immunodeficiency virus, 563
Candida, in human immunodeficiency virus infection, 277
enterovirus 71, in pediatric patients, 850
human T cell lymphotropic virus type I, 857
Leishmania guyanensis, 953
Onchocerca volvulus, 1662
Plasmodium falciparum, vs. human leukocyte antigen type, 168
recovery, in treatment of human immunodeficiency virus infection, 546, 657
schistosomiasis vaccine, chimpanzee model, 1238
tuberculosis, human leukocyte antigens in, 919
Cellulitis, streptococcal group B, in nursing homes, Maryland, 1138
Ceramide, as host defense, against *Escherichia coli,* S47
Ceramide-specific glucosyltransferase inhibitors, for urinary tract infection prevention, mouse model, S70
Cerebrospinal fluid
human immunodeficiency virus in, after treatment, 1318
immune mediators in, in cryptococcosis, in human immunodeficiency virus infection, 294
vascular endothelial growth factor in, in meningitis, 149
Cervix
cancer, human papillomavirus type persistence and, 8
ectopy, in human immunodeficiency virus infection, in adolescent girls, 865
epithelial cells, human immunodeficiency virus sequestration in, 1204
human papillomavirus detection in, in US population, 1554
cg2 gene, *Plasmodium falciparum,* mutations, 789
CGP 4832, uptake by, *Escherichia coli* outer membrane channels, S12
Chemiluminescence assay, for pneumolysin-neutrophil interaction studies, 604
Chemokines and chemokine receptors
in human immunodeficiency virus infection
disease progression and, 1678
dynamics, 736
evolution, 555
polymorphisms, disease progression and, 814, 1574
with tuberculosis, 1801
in Lassa fever, 1713
in malaria, placental, 967
in urinary tract infection defense, S61
Children (*see* Pediatric patients)
Chlamydia pneumoniae, in atherosclerosis pathogenesis, 1368, 1428
antibiotic effects on, 1625
mouse model, 226, 232
Chlamydia trachomatis
infection
cervical ectopy related to, in adolescent girls, 865
in human immunodeficiency virus infection, virus load in, 1405
risk factors for, in low-income women, 1087
omp1 genotype (Ja), 1542
urethritis, 269
Chloroquine
for cryptococcosis, mechanism of action, 935
for *Plasmodium falciparum* malaria, 789, 1417
resistance to
Dictyostelium discoideum, 1653
malaria, 1535, 1543
Plasmodium, 1653
Plasmodium falciparum, 789, 1413, 1417, 1828, 1832
Cholera
drug-resistant, 1701
vaccination, misleading negative findings, 1306, 1308
Cholera toxin, as vaccine adjuvant, with *Streptococcus mutans,* mouse model, 823
Chondroitin sulfate, *Plasmodium falciparum* adherence and, 1165
Chronic fatigue syndrome, post–Lyme disease syndrome resembling, 453
Chronic obstructive pulmonary disease, septicemia with, hospitalization rate due to, in elderly persons, 596
Cilantro, *Salmonella* serotype Thompson infection outbreak related to, 984
Ciprofloxacin, for urinary tract infections, S1
Circumsporozoite protein, *Plasmodium falciparum,* in malaria vaccine, 640
Citrobacter, complicated urinary tract infections, S5
Clodronate, liposome-encapsulated, for Behçet's disease–like symptoms, mouse model, 1180
Cloning, subtractive, in *Escherichia coli* urovirulence gene identification, S21
Clostridium difficile, virulence factors, hamster model, 1760
Coagulopathy
Helicobacter pylori neutrophil-activating protein in, 1055
prevention, in endotoxemia, tissue factor–pathway inhibitor in, 1815

Cognitive function, in Lyme disease, long-term evaluation, 453
Colonization
Candida, in human immunodeficiency virus infection, 286, 355
Clostridium difficile, hamster model, 1760
Escherichia coli, in urinary tract, host response and, S43
pneumococci
epidemiology, Tennessee, 1501
salivary antibody development in, 887
Pseudomonas aeruginosa, 1767
Colorimetry, for pneumolysin-neutrophil interaction studies, 604
Common cold, influenza virus detection in, 1269
Complement, streptococcal inhibitor of, variants, in streptococcal group A infection, 633, 670
Complement 5a, neutrophil responses, in human immunodeficiency virus infection, with tuberculosis, 662
Complement receptor 3
Bordetella pertussis binding to, mouse model, 871
expression, pneumolysin effects on, 604
in *Pseudomonas aeruginosa* phagocytosis, 1214
Condoms, vaginal flora and epithelium effects, 913
Congenital infections (*see also* Human immunodeficiency virus [type 1 or unspecified], transmission, perinatal; Neonatal infections)
cytomegalovirus, vaccination, guinea pig model, 1547
Congestive heart failure, septicemia with, hospitalization rate due to, in elderly persons, 596
Cooley anemia, *Haemophilus influenzae* vaccination in, 1819
Coronary artery disease
Bartonella infection and, 831
Coxiella burnetii infection and, 831
Corticotropin-releasing hormone, in *Schistosoma mansoni* infection, baboon and mouse models, 313
Cortisol, in *Schistosoma mansoni* infection, baboon and mouse models, 313
Coxiella burnetii, coronary artery disease and, 831
C-reactive protein
in enterovirus 71 infection, in pediatric patients, 850
in influenza, in elderly persons, 995
Creutzfeldt-Jakob disease, variant, *PRNP* genotypes and, 192
Cryptococcus neoformans, infection
in human immunodeficiency virus infection
immune mediator levels in, 294
immune response in, interleukin-12 effects on, 51
treatment, 935
mouse model, 1093
Cryptosporidium parvum
infection, outbreak, Milwaukee, 1373
types, in children in Lima, Peru, 492
CsrR/CsrS 2-component regulatory system, streptococci group A, mutations, mouse model, 1043
Culture filtrate protein–10, for extrapulmonary tuberculosis diagnosis, 175
Curli fibers, *Escherichia coli,* nitric oxide synthase induction by, in systemic infection, mouse model, 612
Cyclooxygenase-2, in *Plasmodium falciparum* malaria, vs. severity, in pediatric patients, 113
Cystic fibrosis, *Pseudomonas aeruginosa* infection in
longitudinal study, in children, 444
mouse model, 919
pneumonia, mortality in, type III protein secretion and, 1767
Cystitis
epidemiology, S1
Escherichia coli, virulence factors, 1508
Escherichia coli O18:K1:H7, virulence factors, vs. neonatal meningitis, 425
host defenses
chemokine receptors, S61
fimbriae, mouse model, S51
Toll-like receptor signaling, S61
pathogenesis
bacterial pili in, rodent model, S36
secreted proteins in, mouse model, S32
susceptibility to, S66
treatment, S1
vaccination, animal models, S81
Cytochrome b, *Pneumocystis carinii,* mutations, atovaquone exposure and, 819
Cytokines (*see also specific cytokines*)
in Behçet's disease pathogenesis, mouse model, 1180
in *Cryptococcus neoformans* response, in human immunodeficiency virus infection, interleukin-12 effects on, 51
in endotoxic shock, mouse model, 1617
in Epstein-Barr virus infection, chronic active, 1
in human immunodeficiency virus infection, 1722
in malaria, in pregnancy, 1530
in meningococcal infection, effects of Toll-like receptor blockage on, 89
in *Mycobacterium avium* complex infection, 478
in tuberculosis, with and without human immunodeficiency virus infection, 1805
Cytomegalovirus
in atherosclerosis pathogenesis, mouse model, 226
detection by polymerase chain reaction, before stem-cell transplantation, 377
infection
in human immunodeficiency virus infection
cytokine response in, 1722
ganciclovir resistance, 333
retinitis, 333, 1285
T cell response, 1379, 1399
transfusions in, 1673
in immunodeficiency, vs. *UL4* gene polymorphisms, 218
mouse model, 697
retinitis, in human immunodeficiency virus infection, 333, 1285
replication, in liver transplantation, 179
resistance in, ganciclovir, 333
T cell response to, 835, 1285, 1389
vaccination
canarypox vector with phosphoprotein 65, 1171
guinea pig model, 59, 1547
Cytotoxic necrotizing factor, *Escherichia coli* O18:K1:H7, in cystitis vs. neonatal meningitis, 425

Decay-accelerating factor receptor, *Escherichia coli* Dr adhesin interactions with, in urinary tract infections, S24
Defensins, in urinary tract, S41
Dehydroepiandrosterone sulfate, in *Schistosoma mansoni* infection, baboon and mouse models, 313
Dendritic cells, chemokine receptors on, evolution during early human immunodeficiency virus infection, 555
Desferrioxamine, for *Plasmodium falciparum* malaria, 1388
Diabetes mellitus, septicemia with, hospitalization rate due to, in elderly persons, 596
Diarrhea
astrovirus, epidemiology, Mexico, 681
Campylobacter jejuni
epidemiology, in food handling, 164

invasion antigens, 1607
outbreaks, Hawaii, 1152
Clostridium difficile, virulence factors, hamster model, 1760
Cryptosporidium parvum, types, in children in Lima, Peru, 492
Escherichia coli
nonenteropathogenic, 762
Shiga toxin–producing, hemolytic uremic syndrome after, prospective study, 1063
organisms causing, drug resistance in, 1701
rotavirus, epidemiology, Vietnam, 1707
Salmonella, serotypes, 753
Dictyostelium discoideum, resistance in, chloroquine, 1653
Didanosine, for human immunodeficiency virus infection
dosage, 1539
prophylactic, 707
resistance to, 1688, 1732
Differential agglutination test, for *Toxoplasma gondii,* in pregnancy, 1248
DiGeorge anomaly, immunodeficiency in, multiorgan viral dissemination in, 338
Diphtheria-tetanus toxoids, with subpotent diphtheria component, antitoxin levels in, 1698
DNA viruses, single-stranded, SEN virus as, 359
Dogs, extraintestinal *Escherichia coli* strains in, vs. human strains, 154
Dr adhesins, *Escherichia coli,* in urinary tract infections, S24, 1526
drs gene, mutations, in streptococci group A pharyngitis treatment failure, 670
Drug abuse, injection, hepatitis C RNA levels in, among females, 973
Drug resistance
amoxicillin/clavulanate, 880
ampicillin, *Escherichia coli,* 1526
antiretroviral agents, in human immunodeficiency virus infection, 401
azithromycin, 880
Candida, in human immunodeficiency virus infection, 286
chloroquine
Plasmodium, 1653
Plasmodium falciparum, 789, 1413, 1417, 1535, 1543, 1828, 1832
cytomegalovirus, ganciclovir, 333
diarrheal bacteria, 1701
Dictyostelium discoideum, chloroquine, 1653
didanosine, human immunodeficiency virus, 1732
Escherichia coli, ampicillin, 1526
fluconazole, *Candida,* 286
ganciclovir, cytomegalovirus, 333
human immunodeficiency virus, 1311, 1732
compartmentalization, 143
human leukocyte antigens and, 409, 503
in pediatric patients, 1688
secretory leukocyte protease inhibitor in, 653
T cell replication and, 1009
influenza virus, oseltamivir, 523
nelfinavir, human immunodeficiency virus, 1732
nevirapine, human immunodeficiency virus, 1732
oseltamivir, influenza virus, 523
Plasmodium, chloroquine, 1653
Plasmodium falciparum, chloroquine, 789, 1413, 1417, 1535, 1543, 1828, 1832
pneumococci, otitis media treatment and, 880
ritonavir, human immunodeficiency virus, 1732
Salmonella, 1701
Shigella, 1701
trimethoprim-sulfamethoxazole, 880
in urinary tract infections, S1
Vibrio cholerae, 1701
zalcitabine, human immunodeficiency virus, 1732
zidovudine, human immunodeficiency virus, 1732

eae gene, *Escherichia coli,* in virulence, 762
Ear infections, treatment, superinfection after, 880
Early secretory antigen target, for extrapulmonary tuberculosis diagnosis, 175
Edema, in *Escherichia coli* infection, Shiga toxin antibody in, pig model, 347
Efavirenz, for human immunodeficiency virus infection
dosage, 1539
indinavir with, 392
Ehrlichiosis
mouse model, 1781
transmission, tick removal effects on, mouse model, 773
Elastase, neutrophil, pneumolysin effects on, 604
Elderly persons
influenza in, C-reactive protein and amyloid response in, 995
septicemia hospitalization rate in, United States (1986–1997), 596
streptococcal group B infection in, in nursing homes, 1138
urinary tract infections in, S5
Electrophoresis
Campylobacter jejuni detection, 164
Escherichia coli strains, human-animal similarities, 154
pulsed-field gel
Bordetella pertussis, 1360
Legionella pneumophila serogroup 1 subtyping, 628
ELISA (*see* Enzyme-linked immunosorbent assay)
Emtricitabine, for human immunodeficiency virus infection, dosage, 1539
Encephalitis (*see also* Brain)
enterovirus 71, immune response in, in pediatric patients, 850
Nipah virus, nosocomial transmissibility, 810
Encephalopathy (*see also* Brain)
in Lyme disease, long-term evaluation, 453
Endothelial cells, arterial, *Chlamydia pneumoniae* infection, 1368
Endotoxemia
tissue factor–pathway inhibitor in, 1815
treatment, nitric oxide scavengers for, rat model, 105
Endotoxic shock, Toll-like receptor–4 in, mouse model, 1617
Endotoxin, meningococci deficient in, Toll-like receptor signaling by, 89
Entamoeba histolytica, immune response to, 1787
Enteritis (*see* Gastroenteritis)
Enterobacter, complicated urinary tract infections, S5
Enterococcus, adherence, inhibition, vaginal *Lactobacillus* in, 485
Enterococcus faecalis, vaccination, vaginal mucosal, S81
Enterotoxin
heat-labile, *Escherichia coli,* as vaccine adjuvant
mouse and pig models, 351
mouse model, 1494
staphylococcal, toxic shock syndrome toxin–1 monoclonal antibody inhibition, mouse model, 1739
Enterovirus 71, infection, immune response in, in pediatric patients, 850
env gene, human immunodeficiency virus
in canarypox vaccine vector, 563
evolution, 173, 174
Env protein, human immunodeficiency virus, T cell fusion to, protein disulfide isomerase in, 744
Enzyme immunoassay, for astrovirus, 681

Enzyme-linked immunosorbent assay
for Lewis antigen, in *Helicobacter pylori* infection, 1147
for *Toxoplasma gondii,* in pregnancy, 1248
Epidemiology
anal human papillomavirus infection, in human immunodeficiency virus–positive and at-risk women, 383
astrovirus diarrhea, Mexico, 681
Bordetella pertussis infection
adolescents and adults in Minnesota, 1353
Cincinnati, 1360
Campylobacter jejuni infection
in food handling, 164
Hawaii, 1152
Chlamydia trachomatis infection, San Francisco women, 1087
Cryptosporidium parvum infection, Milwaukee, 1373
diarrhea, rotavirus, Vietnam, 1707
hemolytic uremic syndrome, United States, 1063
hepatitis A, green onions, 1273
human immunodeficiency virus infection, non-B type
Georgia, 138
subtypes, 1311
human papillomavirus carriage, in women, 1554
JC virus genotypes, France, 213
Kaposi's sarcoma–associated herpesvirus, South Texas, 125
Mycoplasma pneumoniae infection, The Netherlands, 675
pertussis
adolescents and adults in Minnesota, 1353
Cincinnati, 1360
pneumococcal carriage, Tennessee, 1501
pneumococcal infection, invasive, United Kingdom, 239
poliomyelitis, Angola, 517
respiratory syncytial virus infection, mortality, United States (1979–1997), 16
Salmonella serotypes, United States, 753
schistosomiasis liver fibrosis, Kenya, 960
septicemia hospitalization, in elderly persons, United States (1986–1997), 596
streptococcal inhibitor of complement variants, streptococcal group A, Finland, 633
streptococci group B infection, in nursing homes, Maryland, 1138
tuberculosis
latent, urban India, 469
in native-born vs. foreign-born persons, Houston, 461
typhoid fever, China, 1775
urinary tract infections, S1
Epstein-Barr virus, infection
chemokine receptor dynamics in, 736
chronic active, virus load and cytokine production in, 1
in immunodeficiency, with Kaposi's sarcoma–associated herpesvirus, 338
Errata
Escherichia coli reference (ECOR) strains (2001;183:78), 1834
extraintestinal *Escherichia coli* isolates (2001;183:154), 357
hepatitis A virus in atherosclerosis pathogenesis (2000;182:1583), 521
Neisseria meningitidis lipopolysaccharide-deficient mutant (2001;183:89), 177
Pneumocystis carinii cytochrome b mutations (2001;183:819), 1170
unweighted pair group method terminology (2001;183:154, 425, 897), 1546
Erythema migrans
in *Borrelia lonestari* infection, 1810
in Lyme disease, long-term evaluation, 453
Erythrocyte membrane protein 1, placental, in malaria, 1165
Escherichia coli
adherence, inhibition, vaginal *Lactobacillus* in, 485
colonization, in urinary tract, host response and, S43
cystitis, virulence factors, 1508
enterohemorrhagic, vaccination, Shiga toxin 2 B subunit in, rabbit model, 435
extraintestinal
human-animal similarities, 154
virulence factors, phylogenetic distribution, 78
fimbriae, in urinary tract host defense, S43, S47, S51, S84
FimCh complex, in vaccination, S81
heat-labile enterotoxin, as vaccine adjuvant, mouse model, 1494
infection
pathophysiology, mouse model, 612
septicemia in, hospitalization rate due to, in elderly persons, 596
Shiga toxin antibody in, pig model, 347
J5 lipopolysaccharide/group B meningococcal outer membrane protein complex vaccination, sepsis, rabbit model, 1079
meningitis, *ibeA* brain microvascular endothelial cell invasion gene in, 1071
nonenteropathogenic, virulence factors, 762
O18:K1:H7, virulence factors, in cystitis vs. neonatal meningitis, 425
resistance in, ampicillin, 1526
Shiga toxin–producing, hemolytic uremic syndrome after, prospective study, 1063
urinary tract infections
complicated, S5
Dr adhesins in, S24
FimH adhesin, S28
mast cell interaction with, mouse model, S51
outer membrane channels, antibiotic uptake and, S12
pathogenicity islands, mouse model, S17, S32
phylogeny and virulence, dog model, 897
pili, rodent model, S36
secreted proteins, mouse model, S32
urovirulence gene isolation, S21
vaginal mucosal vaccination, S81
vaccination
genetically detoxified mucosal adjuvant with, mouse and pig models, 351
vaginal mucosal, S81
vaginal, condom use effects on, 913
virulence factors
dog model, 897
O18:K:H7, 425
in urinary tract infections, S17, S21, S24, S28, S36
fimbriae, S43, S47, S51, S84
Esophagus, aphthous ulcers, in human immunodeficiency virus infection, thalidomide for, 343
Estrogen replacement, for urinary tract infection prevention, S74
Ethambutol, for tuberculosis, whole-blood bactericidal assay, 1300
Ethnic factors, in human immunodeficiency virus progression, 1518
Exb proteins, *Escherichia coli,* in antibiotic uptake facilitation, S12
Eye infections (*see* Retinitis)

Facial palsy, in Lyme disease, long-term evaluation, 453
Factor VIII, porcine, endogenous retrovirus in, transmission to hemophiliacs, 648
Fas and Fas ligand, in tuberculosis, 779
Fc_γ receptor, in *Bordetella pertussis* binding, mouse model, 871
Ferrichrome, *Escherichia coli,* in antibiotic uptake facilitation, S12
Fever, Lassa, inflammatory mediators in, 1713
FhuA protein, *Escherichia coli,* in antibiotic uptake facilitation, S12

Fibrin, deposition, in *Helicobacter pylori* infection, 1055
Fibromyalgia, post–Lyme disease syndrome resembling, 453
Filariasis, *Onchocerca volvulus,* 1662
Fimbriae, *Escherichia coli,* in urinary tract host defense, S43, S47, S51, S84
FimCh complex, *Escherichia coli,* in vaccination, S81
FimH adhesin, *Escherichia coli,* in urinary tract infections, S28
Flow cytometry, for pneumolysin-neutrophil interaction studies, 604
Fluconazole, resistance to, *Candida,* 286
Fluorescence in situ hybridization, *Tropheryma whippellii* localization, 1229
Foodborne diseases
  Campylobacter jejuni
    epidemiology, 164
    outbreaks, Hawaii, 1152
  hepatitis A virus, in green onions, 1273
  Salmonella serotypes, 753
    distribution in food animals after slaughter, 1295
    Thompson, California, 984
Free radicals
  in iron-chelation therapy, for *Plasmodium falciparum* malaria, 1388
  scavengers for, in pneumococcal meningitis, rat model, 247
Fungal infections *(see also specific organisms)*
  granulocyte transfusion in, 321
Fur protein, *Escherichia coli,* in antibiotic uptake facilitation, S12

gag gene, human immunodeficiency virus, in canarypox vaccine vector, 563
Ganciclovir
  for herpesvirus replication, in liver transplantation, 179
  resistance to, cytomegalovirus, 333
Gastritis, *Helicobacter pylori*
  gastric mucosal interleukin-18 expression in, 620
  Lewis antigen expression, 1147
  pathogenesis, 1055
Gastroenteritis, *Cryptosporidium parvum,* Milwaukee, 1373
Gastrointestinal tract, human immunodeficiency virus resistance profiles in, 143
Gender differences, in human immunodeficiency virus progression, 1518
Genetic factors (*see also* Human leukocyte antigens)
  schistosomiasis liver morbidity, 960
  in typhoid fever resistance, 1156
  in urinary tract infections, S66
Genital tract (*see also* Urinary tract infections)
  cytotoxic T cell activity in, human immunodeficiency virus specific, vs. peripheral blood, 977
  herpes simplex virus infection, treatment, guinea pig model, 844
  human immunodeficiency virus shedding in
    macaque model, 1023
    vs. mother-to-child transmission, 206
    after treatment, 1318
  human papillomavirus infection, epidemiology, in women, 1554
  Mycoplasma genitalium infection, 269
  ulcers
    in human immunodeficiency virus infection, virus load in, 1405
    Treponema pallidum subtyping, Arizona, 1601
Giardia lamblia, variant-specific surface proteins, biological selection, mouse model, 119
Glucosyltransferase inhibitors, for urinary tract infection prevention, mouse model, S70
Glycans antibodies, in schistosomiasis vaccine response, chimpanzee model, 1238
Glycoprotein B, antibodies to, in cytomegalovirus modification, guinea pig model, 1547
Glycosphingolipids, urinary tract infection pathogenesis, S66
  mouse model, S70
Glyphosate, for *Cryptococcus neoformans* infection, mouse model, 1093
Gonorrhea, cervical ectopy related to, in adolescent girls, 865
gp120 protein, human immunodeficiency virus
  in *Cryptococcus neoformans* response, interleukin-12 effects on, 51
  in vaccine preparation, 563, 1343
Gram-negative organisms, sepsis, vaccination with *Escherichia coli* J5 lipopolysaccharide/group B meningococcal outer membrane protein complex, rabbit model, 1079
Granulocyte(s), transfusion, current status, 321
Granulocyte colony-stimulating factor
  for granulocyte stimulation, for transfusion, 321
  for pneumococcal pneumonia, mouse model, 70
Gut-associated lymphoid tissue, hyperplasia, in rotavirus infection, mouse model, 1108

HAART (*see* Highly active antiretroviral therapy)
Haemophilus influenzae
  otitis media, treatment, antibiotic resistance development in, 880
  vaccination, in Cooley anemia, 1819
Heart
  cytokine production in, in endotoxic shock, mouse model, 1617
  failure, septicemia with, hospitalization rate due to, in elderly persons, 596
  Lyme disease effects on, mouse model, 1631
  yellow fever effects on, hamster model, 1437
Helicobacter pylori
  in atherosclerosis pathogenesis, 1428
  infection
    gastric mucosal interleukin-18 expression in, 620
    Lewis antigen expression in, 1147
  virulence factors, neutrophil-activating protein as, procoagulant action, 1055
Hemagglutination test
  Escherichia coli O18:K1:H7, in cystitis vs. neonatal meningitis, 425
  parainfluenza virus, 1281
Hemagglutinin, influenza virus, mutation formation in, 523
Hemolysin, *Escherichia coli* O18:K1:H7, in cystitis vs. neonatal meningitis, 425
Hemolytic uremic syndrome
  in *Escherichia coli* infection, Shiga toxin antibody in, pig model, 347
  prospective study, 1063
Hemophilia
  human immunodeficiency virus infection in, hepatitis C with, 589, 1112
  porcine retrovirus transmission to, in porcine factor VIII, 648
Hepatitis, posttransfusion, SEN virus in, 359
Hepatitis A virus, infection, outbreaks, from green onions, 1273
Hepatitis B virus, infection, treatment, monitoring, 1277
Hepatitis C virus
  infection
    atypical antibody pattern, 1428
    in human immunodeficiency virus infection
      in hemophilia, 589, 1112
      liver fibrosis progression in, CD4 cell depletion and, 134
    interferon-γ response in, 1195
    after liver transplantation, T cell response, 1187
    transmission, virus strains in, 666

RNA levels in, among female injection drug users, 973
Herpes simplex virus
in Behçet's disease pathogenesis studies, mouse model, 1180
genital infections, treatment, guinea pig model, 844
Herpesviruses (*see specific viruses, e.g.,* Human herpesvirus 8)
Highly active antiretroviral therapy, for human immunodeficiency virus infection
CD4 T cell recovery in, age influence, 1290
cytomegalovirus-specific T cells in, 1285, 1399
cytomegalovirus viremia in, 1673
discontinuation, quasi-species emergence after, 36
discordant immunologic and virologic response to, 1328
immune recovery after, 657, 1586
lymphocyte telomerase activity and, 417
virus reservoirs in, 1318
subgrouping, 1682
Hippocampus, effects of free-radical scavengers on, in pneumococcal meningitis, rat model, 247
Histoplasmosis, reactivation, mouse model, 1823
HIV infection (*see* Human immunodeficiency virus infection [type 1 or unspecified]; Human immunodeficiency virus infection [type 2])
HLAs (*see* Human leukocyte antigens)
hly gene, *Escherichia coli,* in virulence, 762
Homelessness, tuberculosis epidemiology in, Houston, 461
Hookworm disease, vaccination, hamster model, 1380
Hormone replacement therapy, for urinary tract infection prevention, S74
Host defense (*see also* Cellular immune response; Humoral immune response; Immune response)
surfactant protein A, in *Pneumocystis carinii* susceptibility, mouse model, 943
Trypanosoma brucei gambiense, 988
against urinary tract pathogens (*see* Urinary tract infections, host defenses)
Human granulocytic ehrlichiosis
mouse model, 1781
transmission, tick removal effects on, mouse model, 773
Human herpesvirus 6, replication, in liver transplantation, 179
Human herpesvirus 6A, after bone marrow transplantation, 130
Human herpesvirus 7, replication, in liver transplantation, 179
Human herpesvirus 8 (*see* Kaposi's sarcoma–associated herpesvirus)
Human immunodeficiency virus (type 1 or unspecified)
CD4 T cell binding to, protein disulfide isomerase action in, 744
envelope-targeted toxin, for human immunodeficiency virus infection, mouse model, 1592
epithelial cell sequestration, 1204
in female reproductive tract, cytotoxic T cell activity in, vs. peripheral blood, 977
replication, human leukocyte antigens and, 409, 503
residual, treatment effects on, 1318, 1682
Human immunodeficiency virus infection (type 1 or unspecified)
acute (*see subheading* primary [acute])
advanced, cytomegalovirus infection in, transfusions in, 1673
aphthous ulcers in, thalidomide for, 343
Candida colonization in, 355
candidiasis in
cellular immune response in, 277
drug-resistance evolution in, 286
cervical ectopy in, in adolescent girls, 865
chemokines in (*see* Chemokines and chemokine receptors)
clinical features, 23
Cryptococcus neoformans infection in
immune mediator levels in, 294
immune response effects on, interleukin-12 in, 51
cytomegalovirus infection in
cytokine response in, 1722
ganciclovir resistance in, 333
retinitis, 333, 1285
T cell response, 1285, 1399
transfusions in, 1673
vs. *UL4* gene polymorphisms, 218
env gene evolution, 173, 174
in hemophilia, end-stage liver disease in, 1112
hepatitis C in
hemophilia with, 589
end-stage liver disease in, 1112
liver fibrosis progression in, CD4 cell depletion and, 134
human herpesvirus 8 infection in
genotypes, 125
Kaposi's sarcoma
development time, 1427
incidence, 1304
in women, 1130
human papillomavirus infection in, anal, in women, 383
influenza vaccination in, 1000
JC virus genotypes in, 213
Kaposi's sarcoma in, in women, 1130
lymphadenopathy in, 1833
malaria in, placental chemokine receptors in, 967
measles virus shedding in, 532
meningitis in, *Cryptococcus neoformans,* immune mediator levels in, 294
microbial-induced proviral expression inhibition in, mouse model, 1592
natural history (*see subheadings* nonprogression *and* progression)
non-B
epidemiology, Georgia, 138
subtypes, molecular epidemiology, 1311
nonprogression, T cell proliferation in, 657
pathogenesis
cytokine response in, 1722
protein disulfide isomerase in, 744
in pediatric patients (*see* Pediatric patients, human immunodeficiency virus infection in)
Pneumocystis carinii pneumonia in
cytochrome b mutations in, atovaquone exposure and, 819
survival in, 1409
prevention (*see also subheading* vaccination)
in pediatric patients, 1540
postexposure, 707
primary (acute)
chemokine receptor dynamics in, 736
lymphadenopathy in, 1833
productive T cell infection in, 555
treatment, 1466
in vaccine preparedness cohort, 23
progression
chemokine receptor dynamics in, 1574
early treatment effects on, 1466
with hepatitis C, in hemophilia, 589
in perinatal infection, 814
RANTES production and, 1678
risk factors for, 1518
in tuberculosis, 1801
in prostate epithelial cells, 1204

quasi species
tissue culture studies, 173, 174
after treatment discontinuation, 36
remission, immunologic profile in, 1522
residual disease in, 1318, 1682
resistance in, 1311
compartmentalization, 143
human leukocyte antigens and, 409, 503
in pediatric patients, 1688
secretory leukocyte protease inhibitor in, 653
T cell replication and, 1009
retinitis in, cytomegalovirus, T cell response, 1285
risk factors for, 23
seroconversion in, disease characteristics in, 23
sexually transmitted diseases with, virus load in, 1405
T cells in
canarypox vaccine effects on, 563
in candidiasis, 277
with chemokine receptors, 736
in cytomegalovirus infection, 1285, 1399
deficiency after treatment, interleukin-2 for, 730
depletion, hepatitis C with, liver fibrosis progression and, 134
discordant increases, with virologic treatment failure, 1009
in female reproductive tract vs. peripheral blood, 977
highly active antiretroviral therapy effects on, 1290
naive and memory subpopulations, 1336
in pediatric patients, 1116, 1565
in primary human immunodeficiency virus infection, 555
receptor gene rearrangement, after treatment, 1445
recovery of, after antiretroviral therapy, 546, 657, 722
in remission, 1522
telomerase activity, 417
treatment effects on, in pediatric patients, 1116
in treatment failure, 1522
in tuberculosis, 779
viral fusion to, protein disulfide isomerase in, 744
telomerase activity effects, 417
toxoplasmosis in
cytokine response in, 1722
highly active antiretroviral therapy and, 1586
transmission
perinatal
chemokine receptor dynamics in, 1574
drug resistance in, 1688
human leukocyte antigens and, 503
with lower RNA virus loads, 539
risk factors for, 206
vaginal secretory leukocyte protease inhibitor in, 653
prevention, in pediatric patients, 1540
viral epithelial cell sequestration, 1204
treatment *(see also specific drugs)*
4-drug regimen, 715
antiretroviral agents *(see* Highly active antiretroviral therapy; *specific agents)*
BMS-232632, 1126
combination, 579
discontinuation, quasi-species emergence after, 36
discordant immunologic and virologic response to, 1328
dosage for, 1539
drug holidays in, 1539
failure, 401, 1455, 1732
discordant T cell levels in, 1009
immunologic profile in, 1522
immune reconstitution after, 546, 657, 1586
in pediatric patients, 1445
initiation, 1518
interleukin-2 immunotherapy with, 679, 680, 730, 1476
in pediatric patients, 579, 1116, 1445
phenotypic drug susceptibility testing in, 401
in pregnancy, transmission rate and, 539
primary, 1466
PRO 542 entry inhibitor, 1121
protease genotype variable affecting, 579
residual virus detection, 1318
steady-state trough concentration:inhibitory concentration ratios in, 992, 993
T-20 entry inhibitor, 1121
T cell receptor gene rearrangement excision circles in, in pediatric patients, 1445
T cell subsets after, 722
age influence, 1290
triple-combination, 571
virus reservoirs in, subgrouping, 1682
viral RNA response to, 1455
virus-specific immune recovery after, 546, 657
tuberculosis with
CD88 expression and complement 5a–induced neutrophil response in, 662
chemokine activation in, 1801
cytokine profiles in, 1805
T cell response in, 779
vaccination, 1343
canarypox vector for, 563
preparedness studies for, 23
vaginal infections in, treatment, 1017
virus load in, 23
perinatal transmission and, 539
quasi species in, 36
risk factors and, 1518
in sex workers with sexually transmitted diseases, 1405
treatment effects on, 1455
Human immunodeficiency virus infection (type 2), primary, transmission during, macaque model, 1023
Human leukocyte antigens
anti–human immunodeficiency virus activity and, 409, 503, 504
in cytomegalovirus response, after liver transplantation, 835
vs. *Plasmodium falciparum* immune response, 168
T cells expressing
cytokine production and, in chronic active Epstein-Barr virus infection, 1
in human T cell lymphotropic virus type I infection, 197
tetramers, in CD8 T cell detection, in human immunodeficiency virus infection, 1565
in tuberculosis immune response, 919
in typhoid fever susceptibility, 261
Human neutrophil defensins, in urinary tract, S41
Human papillomavirus
infection
anal, in human immunodeficiency virus infection, in women, 383
genital, in women, 1554
type 16, 8
vaccines, 1485
Human T cell lymphotropic virus type I
infection
pathogenesis, 1305, 1306

T cell response in, 857
T cell subsets in, 197
virus markers in, sequential change of, 1031
Humoral immune response (*see also* Antibody[ies]; Immunoglobulin A; Immunoglobulin G)
Bordetella pertussis, mouse model, 871
canarypox vaccine for human immunodeficiency virus, 563
enterovirus 71, in pediatric patients, 850
schistosomiasis vaccine, chimpanzee model, 1238
Hyaluronate lysase, polymorphisms, in streptococci group, 1694
Hyaluronidase, with pneumococcal nasal inoculation, meningitis development in, mouse model, 1143
Hyperimmune anti–glycoprotein B serum, cytomegalovirus, guinea pig model, 1547
Hypertension, septicemia with, hospitalization rate due to, in elderly persons, 596
Hypotension, in systemic *Escherichia coli* infection, mouse model, 612
Hypothalamic-pituitary-adrenal axis hormones, in *Schistosoma mansoni* infection, baboon and mouse models, 313

ibeA brain microvascular endothelial cell invasion gene, *Escherichia coli,* 1071
IL (*see* Interleukin[s])
Imidazolineoxyl nitric oxide, for shock, rat model, 105
Immune response
amebiasis, 1787
Bordetella pertussis, mouse model, 871
canarypox vaccine for human immunodeficiency virus, 563
Candida, in human immunodeficiency virus infection, 277
Cryptococcus neoformans, in human immunodeficiency virus infection, interleukin-12 effects on, 51
Entamoeba histolytica, 1787
enterovirus 71, in pediatric patients, 850
Giardia lamblia variant-specific surface proteins, biological selection, mouse model, 119
heterotypic, influenza A virus, mouse model, 368
human immunodeficiency virus treatment, 546, 657, 1586
in pediatric patients, 1445
virus specific, 546, 657
human T cell lymphotropic virus type I, 197, 857
ivermectin suppressive therapy, 512
Leishmania guyanensis, 953
meningococcal vaccination
after 5 years, 97
C conjugate comparison, 160
Onchocerca volvulus, 1662
Plasmodium falciparum, vs. human leukocyte antigen type, 168
pneumococci, 887
mouse model, 827
Trypanosoma brucei brucei, mouse model, 1794
tuberculosis, human leukocyte antigens in, 919
urinary tract infections, S66
complicated, S5
as host defense, S66
Immunization (*see* Vaccination)
Immunodeficiency (*see also* Human immunodeficiency virus infection [type 1 or unspecified]; Transplantation)
cytomegalovirus infection in, vs. *UL4* gene polymorphisms, 218
multiorgan viral dissemination in, 338
surfactant protein A deficiency in, *Pneumocystis carinii* infection susceptibility, mouse model, 943
Immunoglobulin A, salivary, in pneumococcal colonization, 887
Immunoglobulin G
high avidity, in toxoplasmosis, in pregnancy, 1248
receptors, in *Bordetella pertussis* binding, mouse model, 871
Immunohistochemistry, pneumococci identification, 1749
Immunotherapy, with interleukin-2, for human immunodeficiency virus infection, 730
Indinavir, for human immunodeficiency virus infection
in 4-drug regimen, 715
efavirenz with, 392
in pediatric patients, 1116
primary, 1466
residual virus burden, 1318
Infants (*see* Neonatal infections; Pediatric patients)
Infectious mononucleosis, virus load and cytokine production in, 1
iNF-γ (*see* Interferon-γ)
Inflammation
Helicobacter pylori neutrophil-activating protein in, 1055
in scrapie, amyloid P measurement in, mouse model, 185
in urinary tract infections, as host defense, S66
Influenza virus
infection
C-reactive protein and amyloid response in, in elderly persons, 995
treatment, oseltamivir, mutant formation in, 523
in nasopharyngeal secretions, in common cold, 1269
type A, heterosubtypic immunity, mouse model, 368
vaccination
in human immunodeficiency virus infection, 1000
methods for, 329
RNA vaccines for, mouse model, 1395
Insulin-like growth factor–2, in *Chlamydia pneumoniae*–induced atherosclerosis enhancement, 1368
Intercellular adhesion molecule–1, in transmesothelial neutrophil migration, interleukin-8 and, 1638
Interferon-γ
in African trypanosomiasis resistance, mouse model, 1794
in atherosclerosis pathogenesis, mouse model, 226
in bacterial meningitis, mouse model, 1749
in *Cryptococcus neoformans* response in human immunodeficiency virus infection, interleukin-12 effects on, 51
in cytomegalovirus infection, mouse model, 697
in Epstein-Barr virus infection, chronic active, 1
for hepatitis C
efficacy, 1195
after liver transplantation, 1187
in human immunodeficiency virus infection, 1722
highly active antiretroviral therapy and, 1586
in ivermectin suppressive therapy, 512
in Lassa fever, 1713
in leishmaniasis treatment, mouse model, 1646
in *Mycobacterium avium* complex infection, 478
in *Onchocerca volvulus,* 1662
in *Plasmodium falciparum* malaria, vs. human leukocyte antigen type, 168
in respiratory syncytial virus infection, 687
in tuberculosis, 779, 919
with and without human immunodeficiency virus infection, 1805
Interferon-inducible protein–10, in Lassa fever, 1713
Interleukin(s)
in bacterial meningitis, mouse model, 1749
in cryptococcosis, in human immunodeficiency virus infection, 294
in cutaneous leishmaniasis, 953
inhibition, chloroquine in, 935

in ivermectin suppressive therapy, 512
in Lassa fever, 1713
in Lyme disease, mouse model, 1631
in malaria, in pregnancy, 1530
Interleukin-1 receptor antagonist, in *Staphylococcus aureus* growth enhancement, 65
Interleukin-1β
in endotoxic shock, mouse model, 1617
peptide fragments, in *Staphylococcus aureus* growth enhancement, 65
Interleukin-2
in Epstein-Barr virus infection, 1
for human immunodeficiency virus infection, 679, 680, 730
with antiretroviral agents, 1476
Interleukin-4
in Behçet's disease pathogenesis, mouse model, 1180
in *Cryptococcus neoformans* response, in human immunodeficiency virus infection, interleukin-12 effects on, 51
for leishmaniasis, mouse model, 1646
in respiratory syncytial virus infection, 687
Interleukin-5, in *Onchocerca volvulus* infection, 1662
Interleukin-6, in Lyme disease, monkey model, 1221
Interleukin-8
in meningococcal infection, effects of Toll-like receptor blockage on, 89
receptor deficiency, urinary tract infection susceptibility in, mouse model, S56
in transmesothelial neutrophil migration, intercellular adhesion molecule–1, 1638
Interleukin-10
in African trypanosomiasis resistance, mouse model, 1794
in aspergillosis, 517
in Epstein-Barr virus infection, 1
in *Mycobacterium avium* complex infection, 478
Interleukin-12
antiretroviral therapy effects on, 546
in *Cryptococcus neoformans* immune response, in human immunodeficiency virus infection, 51
in human immunodeficiency virus infection, 1722
for leishmaniasis, mouse model, 1646
in *Mycobacterium avium* complex infection, 478
Interleukin-18, in gastric mucosa, in *Helicobacter pylori* infection, 620
Intestine, *Tropheryma whippellii* localization in, 1229
Intussusception, in rotavirus infection, mouse model, 1108
Invasion antigens, *Campylobacter jejuni,* 1607
Iron-chelation therapy, for *Plasmodium falciparum* malaria, 1388
Isoniazid, for tuberculosis, whole-blood bactericidal assay, 1300
Ivermectin, for onchocerciasis suppression, in absence of continued exposure, 512

JC virus, genotypes, in France, 213

Kaposi's sarcoma, in human immunodeficiency virus infection, 1304
development time, 1427
in women, 1130
Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8)
epidemiology, South Texas, 125
in immunodeficiency, with Epstein-Barr virus, 338
infection, in human immunodeficiency virus infection
development time, 1427
incidence, 1304
in women, 1130
Kidney
failure, in *Escherichia coli* infection, prospective study, 1063
infection (*see also* Pyelonephritis)
ampicillin-resistant *Escherichia coli,* in pregnancy, 1526
pathology, in ehrlichiosis, mouse model, 1781
transplantation, BK virus infection in, 1669
yellow fever effects on, hamster model, 1437
Klebsiella, complicated urinary tract infections, S5
Klebsiella pneumoniae
adherence, inhibition, vaginal *Lactobacillus* in, 485
vaccination
with *Escherichia coli* J5 lipopolysaccharide/group B meningococcal outer membrane protein complex, rabbit model, 1079
vaginal mucosal, S81
Kuru, susceptibility to, *PRNP* genotypes and, 192

Lactobacillus
in urinary tract infection prevention, S1, S77
vaginal, in uropathogen adhesion inhibition, 485
LamB protein, *Escherichia coli,* in antibiotic uptake facilitation, S12
Lamivudine
for hepatitis B, monitoring, 1277
for human immunodeficiency virus infection
in 4-drug regimen, 715
in pediatric patients, 1116
primary, 1466
prophylactic, 707
residual virus burden, 1318
resistance to, 1688
in triple combination, 571
virus-specific immune recovery after, 546
Laser scanning confocal microscopy, *Tropheryma whippellii* localization, 1229
Lassa fever, inflammatory mediators in, 1713
Learning function, effects of free-radical scavengers on, in pneumococcal meningitis, rat model, 247
Lectin, antibodies to, in amebiasis, 1787
Legionella pneumophila, serogroup 1, subtyping, pulsed-field gel electrophoresis patterns, 628
Leishmania chagasi, infection, dog model, 1421
Leishmaniasis
cutaneous, immune response in, 953
treatment, mouse model, 1646
visceral, dog model, 1421
Leukapheresis, granulocyte stimulation for, 321
Leukocyte adhesion deficiency, *Pseudomonas aeruginosa* phagocytosis in, 1214
Leukocyte count, in enterovirus 71 infection, in pediatric patients, 850
Leukoencephalopathy, progressive multifocal, JC virus genotypes in, France, 213
Levofloxacin, for tuberculosis, whole-blood bactericidal assay, 1300
Lewis antigens, *Helicobacter pylori,* 1147
Lipopolysaccharide (*see* Endotoxin)
Liver
fibrosis, in hepatitis C with human immunodeficiency virus infection, T cell depletion and, 134
inflammation (*see* Hepatitis C virus)
pathology, in ehrlichiosis, mouse model, 1781
schistosomiasis, epidemiology, Kenya, 960
transplantation
CD8 T cell response after, to cytomegalovirus, 835

hepatitis C after, T cell response, 1187
herpesvirus interactions in, 179
yellow fever effects on, hamster model, 1431, 1437
Liver stage antigen type 1, *Plasmodium falciparum,* immune response to, 168
Locus of enterocyte effacement-associated DNA sequences, in nonenteropathogenic *Escherichia coli,* 762
LTK63 heat-labile enterotoxin product, *Escherichia coli,* as vaccine adjuvant, mouse and pig models, 351
Lung
infections (*see* Pneumonia; Tuberculosis)
pathology, in ehrlichiosis, mouse model, 1781
yellow fever effects on, hamster model, 1437
Lyme disease
vs. *Borrelia lonestari* infection, 1810
long-term impact, 453
pathogenesis, monkey model, 1221
pathophysiology, mouse model, 1631
transmission, tick removal effects on, mouse model, 773
Lymphadenopathy, in human immunodeficiency virus infection, 1833
Lymphocyte(s) (*see* B cells; T cells)
Lymphocyte proliferative response, in human immunodeficiency virus infection, highly active antiretroviral therapy and, 1586
Lymphoid tissues
human immunodeficiency virus in, after treatment, 1318
hyperplasia, in rotavirus infection, mouse model, 1108
pathology, in ehrlichiosis, mouse model, 1781
T cells in
human immunodeficiency virus infection, 555
naive and memory subpopulations, human immunodeficiency virus infection and, 1336
yellow fever effects on, hamster model, 1437

Macrolides, for *Chlamydia pneumoniae* infection, cardiovascular disease and, 1625
Macrophage(s)
activation, in tuberculosis, with and without human immunodeficiency virus infection, 1805
Borrelia burgdorferi ingestion, mouse model, 1631
chemokine receptors on
evolution during early human immunodeficiency virus infection, 555
in malaria, 967
placental, in malaria, 967, 1100
tumor necrosis factor–α, in sleeping sickness, 988
Macrophage inflammatory protein–1, in human immunodeficiency virus infection with tuberculosis, 1801
Mad cow disease
inflammatory response in, mouse model, 185
susceptibility to, *PRNP* genotypes and, 192
Malaria
in human immunodeficiency virus infection, 967
mouse model, 1260
placental chemokine receptor measurement in, 967
Plasmodium falciparum
asymptomatic, in pediatric patients, 796
in pregnancy
pathogenesis, 1165
susceptibility to, natural killer cell absence in, 1100
Th1/Th2 disequilibrium in, 1530
resistance in, chloroquine, 1535, 1543
severity
procalcitonin and, 1161
prostaglandin and cyclooxygenase-1 levels in, in pediatric patients, 113
treatment, 789, 1417
artesunate, 1254
iron chelation, 1388
vaccination, circumsporozoite protein type, 640
resistance in, chloroquine, 1535, 1543, 1653, 1828, 1832
Maltoporin, *Escherichia coli,* in antibiotic uptake facilitation, S12
Mast cells, *Escherichia coli* interactions with, in cystitis, mouse model, S51
Mastitis, human immunodeficiency virus transmission and, mother-to-child, 206
Measles
vaccination, thymus damage by, mouse model, 498
virus shedding in, in human immunodeficiency virus infection, 532
Melanization, *Cryptococcus neoformans,* glyphosate effects on, mouse model, 1093
Membrane potential, pneumolysin effects on, 604
Meningitis (*see also* Brain)
bacterial, nitric oxide synthase in, mouse model, 1749
Cryptococcus neoformans, in human immunodeficiency virus infection, immune mediator levels in, 294
Escherichia coli, ibeA brain microvascular endothelial cell invasion gene in, 1071
Escherichia coli O18:K1:H7, virulence factors, vs. cystitis, 425
pneumococcal
epidemiology, United Kingdom, 239
free-radical scavengers in, rat model, 247
pathophysiology, mouse model, 1143
vascular endothelial growth factor detection in, 149
Meningococci (*Neisseria meningitidis*)
lipopolysaccharide deficient, Toll-like receptor signaling by, 89
vaccination
A/C conjugate, 5-year immunologic memory, 97
C conjugate, single dose, 160
with group B outer membrane protein, for sepsis, rabbit model, 1079
Meningoencephalitis, enterovirus 71, immune response in, in pediatric patients, 850
Mesothelium, neutrophil migration across, interleukin-8 in, intercellular adhesion molecule–1 and, 1638
Microfilariasis, *Onchocerca volvulus,* 512, 1662
β_2-Microglobulin, in human immunodeficiency virus infection, virus load and, 1405
Milk, human (*see* Breast-feeding)
Molecular viability assay, *Pneumocystis carinii,* 1825
Monoclonal antibodies, toxic shock syndrome toxin–1, mouse model, 1739
Monocytes, placental, in malaria, 1100
Mononucleosis, infectious, virus load and cytokine production in, 1
Mortality
enterovirus 71 infection, in pediatric patients, 850
influenza, in elderly persons, 995
Lassa fever, 1713
malaria, procalcitonin and, 1161
Pneumocystis carinii pneumonia, in human immunodeficiency virus infection, 1409
Pseudomonas aeruginosa infection, type III protein secretion and, 1767
respiratory syncytial virus infection, United States (1979–1997), 16
septicemia, in elderly persons, United States (1986–1997), 596
yellow fever, hamster model, 1431
Moxifloxacin, for tuberculosis, whole-blood bactericidal assay, 1300

Mucosal vaccination, LTK63 heat-labile enterotoxin product for, mouse and pig models, 351
drug resistance due to (*see* Drug resistance)
Mycobacterium avium complex, infection
cytokine profiles in, 478
in human immunodeficiency virus infection, viral expression in, mouse model, 1592
Mycobacterium tuberculosis (*see* Tuberculosis)
Mycoplasma genitalium, urethritis, 269
Mycoplasma pneumoniae
reservoirs for, children as, 675
respiratory infections, epidemiology, The Netherlands, 675
Myelopathy, human T cell lymphotropic virus type I–associated
pathogenesis, 1305, 1306
T cell subsets in, 197, 857
Myocardial infarction, *Chlamydia pneumoniae* infection and, antibiotic effects on, 1625
Myocardium, cytokine production in, in endotoxic shock, mouse model, 1617

Natural killer cells, absence, in placental malaria, 1100
Natural resistance–associated macrophage protein 1, in typhoid fever resistance, 1156
Neisseria gonorrhoeae, infection
cervical ectopy related to, in adolescent girls, 865
in human immunodeficiency virus infection, virus load in, 1405
Neisseria meningitidis (*see* Meningococci)
Nelfinavir, for human immunodeficiency virus infection, resistance to, 1688, 1732
Neonatal infections (*see also* Pediatric patients)
cytomegalovirus, vaccination for, guinea pig model, 59
Escherichia coli, ibeA brain microvascular endothelial cell invasion gene in, 1071
Escherichia coli O18:K1:H7 meningitis, virulence factors, vs. adult cystitis, 425
granulocyte transfusion in, 321
human immunodeficiency infection
from breast-feeding, 206
human leukocyte antigens and, 503
Plasmodium falciparum malaria, asymptomatic, 796
Toxoplasma gondii, prophylaxis, 1248
Nephropathy, BK virus, in kidney transplantation, 1669
Neuraminidase inhibitors, for influenza, mutant formation in, 523
Neuroborreliosis, long-term evaluation, 453
Neurologic infections (*see also* Encephalitis; Encephalopathy; Meningitis)
Lyme disease, long-term impact, 453
Neutropenia, granulocyte transfusion in, current status, 321
Neutrophil(s)
defensins in, in urinary tract, S41
impaired response, in human immunodeficiency virus infection, with tuberculosis, 662
pneumolysin interactions with, 604
transfusion, current status, 321
Neutrophil-activating protein, *Helicobacter pylori,* as virulence factor, procoagulant action, 1055
Nevirapine, for human immunodeficiency virus infection
in 4-drug regimen, 715
resistance to, 1688, 1732
Nicotinamide auxotrophy, *Escherichia coli* O18:K1:H7, in cystitis vs. neonatal meningitis, 425
Nipah virus, encephalitis, nosocomial transmissibility, 810
Nitric oxide, formation
in endotoxic shock, mouse model, 1617
in iron-chelation therapy, for *Plasmodium falciparum* malaria, 1388
in systemic *Escherichia coli* infection, mouse model, 612
Nitric oxide scavengers, for shock, rat model, 105
Nitric oxide synthase
in bacterial meningitis, mouse model, 1749
in tuberculosis, with and without human immunodeficiency virus infection, 1805
Nitrogen dioxide, in prostaglandin synthase inactivation, rat model, 105
Nose
immunization in, influenza, 329
influenza virus detection in, in common cold, 1269
pneumococcal inoculation, meningitis development in, mouse model, 1143
Nosocomial infections
catheter related
urinary, S1
vascular, 1038
Mycoplasma pneumoniae, prophylaxis, 907
Nipah virus encephalitis, transmissibility, 810
streptococci group B, in nursing homes, Maryland, 1138
NRAMP1 gene, in typhoid fever resistance, 1156
Nuclear factor–κB, in endotoxic shock, mouse model, 1617

Ofloxacin, for urinary tract infections, S1
Onchocerciasis
immune response in, 1662
suppressive therapy, in absence of continued exposure, 512
Opsonization, *Bordetella pertussis,* mouse model, 871
Oral cavity
aphthous ulcers, in human immunodeficiency virus infection, thalidomide for, 343
Candida colonization, in human immunodeficiency virus infection, 355
candidiasis
drug resistance in, 286
in human immunodeficiency virus infection, immune response in, 277
Pseudomonas aeruginosa detection in, in cystic fibrosis, longitudinal study, 444
Oral contraceptives, cervical ectopy related to, in adolescent girls, 865
Oseltamivir, for influenza, mutant formation in, 523
Otitis media
pneumococcal, antibody development in, 887
treatment, superinfection after, 880
Outbreaks
Campylobacter jejuni infection, Hawaii, 1152
Cryptosporidium parvum infection, Milwaukee, 1373
hepatitis A, from green onions, 1273
Mycoplasma pneumoniae infection, prophylaxis, 907
Salmonella serotype Thompson infection, California, 984
typhoid fever, China, 1775
Outer membrane channels
Escherichia coli, antibiotic uptake in, S12
Escherichia coli O18:K1:H7, in cystitis vs. neonatal meningitis, 425
Oxygen free radicals, in iron-chelation therapy, for *Plasmodium falciparum* malaria, 1388

p24 antigen, human immunodeficiency virus
Pancreas, necrosis, in yellow fever, hamster model, 1437
immune response to, after antiretroviral therapy, 546

microbial-induced expression, mouse model, 1592
papA gene, *Escherichia coli,* DNA sequence diversity, virulence and, 78
Papillomavirus (*see* Human papillomavirus)
Parainfluenza virus type 3, infection, maternal antibody half-life and, in pediatric patients, 1281
Paromomycin, for leishmaniasis, mouse model, 1646
Parvovirus B19, vaccination, 805
Pathogenicity islands, *Escherichia coli,* in urinary tract infections, S17
mouse model, S17, S32
PCR (*see* Polymerase chain reaction)
Pediatric patients (*see also* Neonatal infections)
astrovirus diarrhea in, molecular epidemiology, Mexico, 681
Cryptosporidium parvum types in, Lima, Peru, 492
cystic fibrosis in, *Pseudomonas aeruginosa* detection in, longitudinal study, 444
enterovirus 71 infection in, immune response in, 850
granulocyte transfusion in, 321
Helicobacter pylori infection in, Lewis antigen expression, 1147
human immunodeficiency virus infection in
CD8 T cells in, 1565
chemokine receptor polymorphisms in, 814, 1574
drug resistance in, 1688, 1732
measles virus shedding in, 532
prevention, 1540
transmission, 206
treatment, 1116
combination, 579
immune reconstitution after, 1445
malaria in
asymptomatic, 796
severity, vs. cyclooxygenase-2 and prostaglandin levels, 113
measles virus shedding in, in human immunodeficiency virus infection, 532
multiorgan viral dissemination in, in primary immunodeficiency, 338
as *Mycoplasma pneumoniae* reservoirs, 675
parainfluenza virus type 3 infection in, maternal antibody half-life and, 1281
pneumococcal antibody development in, 880
respiratory syncytial virus infection in, cytokine response in, 687
rotavirus diarrhea in, epidemiology, Vietnam, 1707
Penicillin(s), for *Chlamydia pneumoniae* infection, cardiovascular disease and, 1625
Pertussis
epidemiology
adolescents and adults in Minnesota, 1353
Cincinnati, 1360
immune response in, mouse model, 871
Peyer's patches, hyperplasia, in rotavirus infection, mouse model, 1108
pfcrt gene mutations, *Plasmodium falciparum,* 789, 1535, 1543, 1653, 1828, 1832
P fimbriae, *Escherichia coli,* in urinary tract host defense, S43, S47
pfmdr1 gene, *Plasmodium falciparum,* mutations, 789, 1535
Phagocytosis
Bordetella pertussis, mouse model, 871
Pseudomonas aeruginosa, receptor mediation, 1214
Phagolysome, *Cryptococcus neoformans,* chloroquine action on, 935
Pharyngitis, streptococcal group A
streptococcal inhibitor of complement variants in, 633, 670
treatment failure, isolate characterization in, 670
Pharynx
Candida colonization, in human immunodeficiency virus infection, 355
candidiasis, in human immunodeficiency virus infection, immune response in, 277
Pseudomonas aeruginosa detection in, in cystic fibrosis, longitudinal study, 444
α-Phenyl-*tert*-butyl nitrone, in pneumococcal meningitis, rat model, 247
Phospholipase A_2, pneumolysin effects on, 604
Phosphoprotein 65, in cytomegalovirus vaccine preparation, 1171
Phytohemagglutinin, immune response to, in human immunodeficiency virus infection, antiretroviral therapy effects on, 546
Pili, *Escherichia coli,* in urinary tract infections, S36
Placenta
chemokine receptors in, in malaria, 967
erythrocyte membrane protein 1 in, in malaria, 1165
natural killer cell absence in, malaria susceptibility and, 1100
Th1/Th2 disequilibrium in, in malaria, 1530
Plasminogen activator inhibitor–2, *Helicobacter pylori* neutrophil-activating protein stimulation, 1055
Plasmodium, resistance in, chloroquine, 1653
Plasmodium chabaudi chabaudi malaria, in human immunodeficiency virus infection, mouse model, 1260
Plasmodium falciparum, malaria
asymptomatic, in pediatric patients, 796
circumsporozoite protein type, 640
immune response, vs. human leukocyte antigen type, 168
in pregnancy
pathogenesis, 1165
susceptibility to, natural killer cell absence in, 1100
Th1/Th2 disequilibrium in, 1530
resistance in, chloroquine, 789, 1413, 1417, 1535, 1543, 1653, 1828, 1832
severity
procalcitonin and, 1161
prostaglandin and cyclooxygenase-1 levels in, in pediatric patients, 113
transmission, to *Anopheles gambiae,* artesunate effects, 1254
treatment, 789, 1417
artesunate, 1254
iron chelation, 1388
vaccination, monkey model, 303
Plasmodium vivax, resistance in, chloroquine, 1653
Pleuritis, parvovirus B19, vaccination for, 805
Pneumococci (*Streptococcus pneumoniae*)
antibodies, development, in colonization, 887
bacteremia, pneumolysin antibody protection in, mouse model, 827
colonization
antibody development in, 887
epidemiology, Tennessee, 1501
genotyping, 1501
invasive infections, epidemiology
Tennessee, 1501
United Kingdom, 239
meningitis
free-radical scavengers in, rat model, 247
nitric oxide synthase in, mouse model, 1749
pathophysiology, mouse model, 1143
pneumonia, treatment with granulocyte colony-stimulating factor, mouse model, 70
resistance in, otitis media treatment and, 880

superinfections, otitis media treatment and, 880
vaccination
conjugate, serotypes 6A and 6B, mouse model, 253
epidemiologic studies for, United Kingdom, 239
intranasal, mouse model, 1494
Pneumocystis carinii
infection, susceptibility to, mouse, 943
molecular viability assay for, 1825
pneumonia, in human immunodeficiency virus infection
cytochrome b mutations in, atovaquone exposure and, 819
survival in, 1409
Pneumolysin
antibodies to
in pneumococcal bacteremia, mouse model, 827
in pneumococcal colonization, 887
neutrophil interactions with, 604
Pneumonia
Mycoplasma pneumoniae, prophylaxis, 907
parvovirus B19, vaccination for, 805
pneumococcal
treatment with granulocyte colony-stimulating factor, mouse model, 70
vaccination, conjugate, serotypes 6A and 6B, mouse model, 253
Pneumocystis carinii
molecular viability assay for, 1825
susceptibility to, mouse model, 943
Pseudomonas aeruginosa, mortality in, type III protein secretion and, 1767
respiratory syncytial virus, mortality, United States (1979–1997), 16
septicemia in, hospitalization rate due to, in elderly persons, 596
streptococcal group B, in nursing homes, Maryland, 1138
Poliomyelitis
epidemiology, Angola, 517
vaccination, disease outbreak after, 517
Polymerase chain reaction
for *Borrelia burgdorferi,* 773
for cytokines, in Epstein-Barr virus infection, 1
for *Ehrlichia phagocytophila,* 773
for *Escherichia coli,* urovirulence genes, S21
for hepatitis C virus, in female injection drug users, 973
for human herpesvirus 6A detection, 130
for human immunodeficiency virus, 1682
in quasi-species detection, 36
for human papillomavirus
in human immunodeficiency virus infection, 383
type 16, 8
for Kaposi's sarcoma–associated herpesvirus, 125
multiplex, for *Escherichia coli* O18:K1:H7, in cystitis vs. neonatal meningitis, 425
for *Mycoplasma pneumoniae,* 675, 907
for *Plasmodium falciparum* mutations, 789
for *Pneumocystis carinii* mutations, 819
quantitative real-time, for cytomegalovirus, before stem-cell transplantation, 377
reverse transcription
for astrovirus, 681
for hepatitis C virus strains, in transfusion recipients, 666
for measles virus, in human immunodeficiency virus infection, 532
for pneumococci, 1749
for porcine endogenous retrovirus, 648
for *Treponema pallidum,* Arizona, 1601
Polysaccharide intercellular adhesin, *Staphylococcus epidermidis,* in catheter infection pathogenesis, rat model, 1038
Porcine endogenous retroviruses, transmission, in porcine factor VIII, to hemophiliacs, 648
Porins, *Escherichia coli,* in antibiotic uptake facilitation, S12
Potassium, neutrophil permeability to, pneumolysin effects on, 604
Prednisolone, for human immunodeficiency virus infection, mouse model, 1592
Pregnancy
cytomegalovirus vaccination in, guinea pig model, 1547
human immunodeficiency virus infection in (*see also* Human immunodeficiency virus infection [type 1 or unspecified], transmission, perinatal)
prophylactic zidovudine in, 1540
malaria in
pathogenesis, 1165
placental chemokine receptors in, 967
susceptibility to, natural killer cell absence in, 1100
Th1/Th2 disequilibrium in, 1530
pyelonephritis in, ampicillin-resistant *Escherichia coli,* 1526
toxoplasmosis in, immunoglobulin G avidity testing in, 1248
PRNP gene, genotypes, spongiform encephalopathy susceptibility and, 192
PRO 542 entry inhibitor, for human immunodeficiency virus infection, 1121
Probe hybridization, *Escherichia coli* O18:K1:H7, in cystitis vs. neonatal meningitis, 425
Procalcitonin, malaria severity and, 1161
pro gene, human immunodeficiency virus, in canarypox vaccine vector, 563
Progressive multifocal leukoencephalopathy, JC virus genotypes in, France, 213
Prophylaxis
human immunodeficiency virus infection
in pediatric patients, 1540
postexposure, 707
Mycoplasma pneumoniae, during hospital outbreak, 907
toxoplasmosis, neonatal, 1248
urinary tract infections (*see* Urinary tract infections, prevention)
Prostaglandin(s), in *Plasmodium falciparum* malaria, vs. severity, in pediatric patients, 113
Prostaglandin synthase, inactivation, nitrogen dioxide in, rat model, 105
Prostate, epithelial cells, human immunodeficiency virus sequestration in, 1204
Protease(s), genotypes of, in human immunodeficiency virus treatment outcome, 579
Protease inhibitors *(see also specific drugs)*
for human immunodeficiency virus infection, steady-state trough concentration:inhibitory concentration ratios in, 992, 993
secretory, in vaginal fluid, human immunodeficiency virus transmission and, 653
Protein disulfide isomerase, in human immunodeficiency virus–T cell fusion, 744
Proteus mirabilis
adherence, inhibition, vaginal *Lactobacillus* in, 485
urinary tract infections, complicated, S5
vaccination, vaginal mucosal, S81
Proteus morganii, vaccination, vaginal mucosal, S81
Providencia stuartii, urinary tract infections, complicated, S5
prtF1 gene, mutations, in streptococci group A pharyngitis treatment failure, 670
Pseudomonas aeruginosa
adherence, inhibition, vaginal *Lactobacillus* in, 485

detection, in cystic fibrosis, longitudinal study, in children, 444
infection
in cystic fibrosis, mouse model, 919
mortality in, type III protein secretion and, 1767
urinary tract, S5
phagocytosis, receptor mediation, 1214
vaccination with *Escherichia coli* J5 lipopolysaccharide/group B meningococcal outer membrane protein complex, rabbit model, 1079
Pulsed-field gel electrophoresis
for *Campylobacter jejuni* detection, 164
for *Escherichia coli* strains, human-animal similarities, 154
for *Legionella pneumophila* serogroup 1 subtyping, 628
Putative siderophore, *Escherichia coli* O18:K1:H7, in cystitis vs. neonatal meningitis, 425
Pyelonephritis
ampicillin-resistant *Escherichia coli,* in pregnancy, 1526
complicated, S5
epidemiology, S1
host defenses
chemokine receptors, S61
Toll-like receptor signaling, S61
pathogenesis, secreted proteins in, mouse model, S32
susceptibility to, S66
in interleukin-8 receptor deficiency, mouse model, S56
treatment, S1
vaccination, animal models, S81
Pyrazinamide, for tuberculosis, whole-blood bactericidal assay, 1300

R-848 (resiquimod), for genital herpes simplex virus infection, guinea pig model, 844
Radiometric assay, for pneumolysin-neutrophil interaction studies, 604
RANTES
human immunodeficiency virus infection progression and, 1678
in Lassa fever, 1713
Rapid antigen-detection test, for group A streptococci, false-positive result, 1135
RD1 antigen, *Mycobacterium tuberculosis,* T cells specific for, in latent tuberculosis, urban India, 469
Regulated upon activation, normal T cell expressed and secreted (*see* RANTES)
Resiquimod, for genital herpes simplex virus infection, guinea pig model, 844
Resistance, drug (*see* Drug resistance)
Respiratory infections (*see also* Pneumonia; Tuberculosis)
false-positive rapid antigen-detection test results in, 1135
Mycoplasma pneumoniae, epidemiology, The Netherlands, 675
Pseudomonas aeruginosa
in cystic fibrosis, mouse model, 919
mortality in, type III protein secretion and, 1767
Respiratory syncytial virus
infection
cytokine response in, 687
mortality in, United States (1979–1997), 16
treatment, cotton rat model, 1425
vaccination, RNA vaccines for, mouse model, 1395
Retinitis, cytomegalovirus, in human immunodeficiency virus infection
ganciclovir resistance in, 333
T cell response, 1285
Reverse transcriptase–polymerase chain reaction, for influenza virus, 1269
Rheumatic heart disease, pathogenesis, 507
Rifampin, for tuberculosis, whole-blood bactericidal assay, 1300
Rifamycin, uptake, *Escherichia coli* outer membrane channels, S12
Ritonavir, for human immunodeficiency virus infection
resistance to, 1688, 1732
steady-state trough concentration:inhibitory concentration ratios in, 992, 993
virus-specific immune recovery after, 546
River blindness, immune response in, 1662
RNA vaccines, self-replicative, mouse model, 1395
Rotavirus
diarrhea, epidemiology, Vietnam, 1707
infection, intussusception in, mouse model, 1108

Saliva, antibody formation in, in pneumococcal colonization, 887
Salmonella
epidemiology, serotypes in, United States, 753
resistance to, 1701
serotype Thompson infection, outbreaks, California, 984
transmission, serotype distribution in food animals after slaughter and, 1295
Salmonella typhi (*see* Typhoid fever)
Saquinavir, for human immunodeficiency virus infection
interleukin-2 with, 1476
steady-state trough concentration:inhibitory concentration ratios in, 992, 993
virus-specific immune recovery after, 546
Sarcoma, Kaposi's (*see* Kaposi's sarcoma)
Sat protein, *Escherichia coli,* in urinary tract infections, mouse model, S32
Schistosomiasis
hypothalamic-pituitary-adrenal axis hormones in, baboon and mouse models, 313
liver fibrosis in, epidemiology, Kenya, 960
vaccination, chimpanzee model, 1238
Scrapie, inflammatory response in, mouse model, 185
Secretory leukocyte protease inhibitor, vaginal, human immunodeficiency virus transmission and, 653
Semen, human immunodeficiency virus load in
in early disease, 23
during primary infection, macaque model, 1023
SEN virus, genomic and molecular evolutionary analysis of, 359
Sepsis
Toll-like receptor–4 in, mouse model, 1617
vaccination, J5 *Escherichia coli* lipopolysaccharide/group B meningococcal outer membrane protein complex, rabbit model, 1079
Septicemia, hospitalization due to, in elderly persons, United States (1986–1997), 596
Septic shock
Escherichia coli, pathophysiology, mouse model, 612
treatment, nitric oxide scavengers for, rat model, 105
Serratia, complicated urinary tract infections, S5
Sexual activity, vaginal effects, condom effects on, 913
Sexually transmitted diseases *(see also specific diseases)*
in human immunodeficiency virus infection, virus load in, 1405
women at risk for, anal human papillomavirus infection in, 383
Sex workers, human immunodeficiency virus infection in, with sexually transmitted diseases, virus load in, 1405
Shiga toxin
absence, in nonenteropathogenic *Escherichia coli,* 762
antibody, in *Escherichia coli* infection, pig model, 347
Escherichia coli, hemolytic uremic syndrome resulting from, prospective study, 1063

Shiga toxin 2 B subunit, in enterohemorrhagic *Escherichia coli* vaccination, rabbit model, 435
Shigella, resistance to, 1701
Shock
  endotoxic, Toll-like receptor–4 in, mouse model, 1617
  septic
    Escherichia coli, pathophysiology, mouse model, 612
    treatment, nitric oxide scavengers for, rat model, 105
  toxic, toxin-1 monoclonal antibody, mouse model, 1739
Sic (streptococcal inhibitor of complement) protein, streptococcal group A, variants, 670
  epidemiology, Finland, 633
Simian immunodeficiency virus infection, transmission, macaque model, 1023
Skin lesions
  Borrelia lonestari, 1810
  Ehrlichia, mouse model, 1781
  Leishmania guyanensis, immune response in, 953
  Leishmania major, treatment, mouse model, 1646
  streptococci group A, virulence factors, mouse model, 1043
Sleeping sickness
  resistance to, mouse model, 1794
  tumor necrosis factor–α in, 988
Sliding window bootstrap analysis, of human immunodeficiency virus subtypes, 138
Soft-tissue infections, streptococci group A, virulence factors, mouse model, 1043
Spectrofluorometry, for pneumolysin-neutrophil interaction studies, 604
Spiramycin, for *Toxoplasma gondii* infection, prophylactic, 1248
Spleen, yellow fever virus in, hamster model, 1437
Splenectomy, in thalassemia, *Haemophilus influenzae* vaccination after, 1819
Spongiform encephalopathy
  inflammatory response in, mouse model, 185
  susceptibility to, *PRNP* genotypes and, 192
Staphylococci
  infection, septicemia in, hospitalization rate due to, in elderly persons, 596
  toxic shock syndrome toxin–1, monoclonal antibody to, mouse model, 1739
Staphylococcus aureus
  adherence, inhibition, vaginal *Lactobacillus* in, 485
  extracellular growth, interleukin effects on, 65
  in transmesothelial neutrophil migration, 1638
  urinary tract infections, S5
Staphylococcus epidermidis, catheter infection, pathogenesis, rat model, 1038
Staphylococcus saprophyticus, adherence, inhibition, vaginal *Lactobacillus* in, 485
Stavudine, for human immunodeficiency virus infection
  in 4-drug regimen, 715
  prophylactic, 707
  resistance to, 1688
  virus-specific immune recovery after, 546
Steatosis, in yellow fever, hamster model, 1437
Stem-cell transplantation, cytomegalovirus detection before, 377
Streptococcal inhibitor of complement, streptococcal group A, variants, 670
  epidemiology, Finland, 633
Streptococci
  group A *(Streptococcus pyogenes)*
    infection
      streptococcal inhibitor of complement variants in, 633, 670
      treatment, failure, isolate characterization in, 670
    rapid antigen-detection test for, false-positive result, 1135
    virulence factors, mouse model, 1043
  group B
    infection, in nursing homes, Maryland, 1138
    serotype III, phylogenetic classification, 1694
  infection, rheumatic carditis in, pathogenesis, 507
  urinary tract infections, S5
Streptococcus milleri group, false-positive rapid antigen-detection test results and, 1135
Streptococcus mutans, vaccination, with cholera toxin adjuvant, mouse model, 823
Streptococcus pneumoniae (*see* Pneumococci)
Streptococcus pyogenes (*see* Streptococci, group A)
Stroke, *Chlamydia pneumoniae* infection and, antibiotic effects on, 1625
Subtractive cloning, in *Escherichia coli* urovirulence gene identification, S21
Superinfections, pneumococcal, after otitis media treatment, 880
Superoxide, in neutrophils, pneumolysin effects on, 604
Surface adhesin A, pneumococcal, antibodies to, in pneumococcal colonization, 887
Surface protein A, pneumococcal, antibodies to, in pneumococcal colonization, 887
Surfactant protein A deficiency, *Pneumocystis carinii* infection susceptibility in, mouse model, 943
Surveillance, human immunodeficiency virus non-B subtypes, 1311
Survival (*see also* Mortality)
  in *Pneumocystis carinii* pneumonia, in human immunodeficiency virus infection, 1409
Susceptibility
  antiretroviral agents, in human immunodeficiency virus infection, 401
  Mycobacterium tuberculosis, whole-blood bactericidal assay for, 1300
Syphilis, in human immunodeficiency virus infection, virus load in, 1405

T-20 entry inhibitor, for human immunodeficiency virus infection, 1121
Tacrolimus, in liver transplantation, T cell cytomegalovirus response, 835
Tamm-Horsfall glycoprotein, as host defense mechanism, S66
TARGET (Triple Antiretroviral GlaxoWellcome Experience Trial), for human immunodeficiency virus treatment, 571
T cell receptor, excision circles
  gene rearrangement in, human immunodeficiency virus therapy effects on, 1445
  in treatment evaluation, 1522
T cells
  apoptosis of, in tuberculosis, 779
  CD4
    in cytomegalovirus infection
      in human immunodeficiency virus infection, 1285
      mouse model, 697
    depletion, in human immunodeficiency virus infection, hepatitis C with, liver fibrosis progression and, 134
    hepatitis C virus specific, after liver transplantation, 1187
    in human immunodeficiency virus infection
      with chemokine receptors, 736
      discordant increases, with virologic treatment failure, 1009
      in highly active antiretroviral therapy, 1290

viral fusion to, protein disulfide isomerase in, 744
in Lyme disease, monkey model, 1221
telomerase activity, in human immunodeficiency virus infection, 417
CD8
in cytomegalovirus infection
after liver transplantation, 835
mouse model, 697
in heterotypic immune response to influenza A virus, mouse model, 368
in human immunodeficiency virus infection
canarypox vaccine effects on, 563
in pediatric patients, 1565
recovery of, after antiretroviral therapy, 722
in human T cell lymphotropic virus type I infection, 197
in respiratory syncytial virus infection, 687
in tuberculosis, 919
Cryptococcus neoformans response, interleukin-12 effects on, 51
cytotoxic
in cytomegalovirus vaccine response, 1171
in human immunodeficiency virus infection
in female reproductive tract, vs. peripheral blood, 977
recovery of, after antiretroviral therapy, 722
in respiratory syncytial virus infection, 687
effector, in human T cell lymphotropic virus type I infection, 197
in enterovirus 71 infection, in pediatric patients, 850
Epstein-Barr virus load in, in chronic active infection, cytokine production and, 1
helper
in malaria, in placenta, 1530
in parvovirus B19 vaccination, 805
in human immunodeficiency virus infection (*see* Human immunodeficiency virus infection [type 1 or unspecified], T cells in)
in human T cell lymphotropic virus type I infection, 197
in leishmaniasis, 953
memory, in human T cell lymphotropic virus type I infection, 197
Mycobacterium tuberculosis RD1 antigen specific, in latent tuberculosis, urban India, 469
response
in *Helicobacter pylori* infection, 620
to *Plasmodium falciparum,* vs. human leukocyte antigen type, 168
Th2, in Behçet's disease pathogenesis, mouse model, 1180
Telomerase, human immunodeficiency virus effects on, 417
Thalassemia, *Haemophilus influenzae* vaccination in, 1819
Thalidomide, for aphthous ulcers, in human immunodeficiency virus infection, 343
Thrombocytopenia, in hemolytic uremic syndrome, 1063
Thymus
measles vaccine damage, vs. virus strain, mouse model, 498
T cell replication in, in human immunodeficiency virus treatment failure, 1009
Ticks, in disease transmission
Borrelia lonestari, 1810
Lyme disease, removal time and, mouse model, 773
tickborne encephalitis virus, vaccination, mouse model, 1395
Tissue culture, human immunodeficiency virus *env* gene, for evolutionary studies, 173, 174
Tissue factor, *Helicobacter pylori* neutrophil-activating protein stimulation, 1055
Tissue factor–pathway inhibitor, in endotoxemia, 1815
TNF-α (*see* Tumor necrosis factor–α)
Toll-like receptors
in endotoxic shock, mouse model, 1617
lipopolysaccharide-deficient meningococci signaling by, 89
in urinary tract infection defense, S61
TonB protein, *Escherichia coli,* in antibiotic uptake facilitation, S12
Toxic shock syndrome, toxin-1, monoclonal antibody to, mouse model, 1739
Toxins, *Pseudomonas aeruginosa,* 1767
Toxoplasmosis
in human immunodeficiency virus infection
cytokine response in, 1722
highly active antiretroviral therapy and, 1586
in pregnancy, immunoglobulin G avidity testing in, 1248
Transforming growth factor–β, in Epstein-Barr virus infection, chronic active, 1
Transfusions
hepatitis C virus transmission in, virus strains in, 666
in human immunodeficiency virus infection, cytomegaloviremia and, 1673
porcine factor VIII, porcine endogenous retrovirus transmission in, 648
SEN virus transmission in, 359
Transmembrane signaling, *Escherichia coli,* S47
Transmissible spongiform encephalopathy
inflammatory response in, mouse model, 185
susceptibility to, *PRNP* genotypes and, 192
Transplantation
bone marrow, human herpesvirus 6A detection after, 130
kidney, BK virus infection in, 1669
liver
CD8 T cell response after, to cytomegalovirus, 835
hepatitis C after, T cell response, 1187
herpesvirus interactions in, 179
stem cell, cytomegalovirus detection before, 377
Treponema pallidum, molecular subtyping, vs. disease morbidity, Arizona, 1601
Trichomoniasis, in human immunodeficiency virus infection
virus load in, 1405
virus shedding and, 1017
Trimethoprim-sulfamethoxazole
resistance to, 880
for urinary tract infections, S1
Tropheryma whippellii, localization in tissue, 1229
Tropical spastic paraparesis
pathogenesis, 1305, 1306
T cell subsets in, 197, 857
Trypanosoma brucei gambiense, infection, tumor necrosis factor–α in, 988
Trypanosomiasis, African, resistance to, mouse model, 1794
Tsx protein, *Escherichia coli,* in antibiotic uptake facilitation, S12
TT virus, SEN virus relationship to, 359
Tuberculosis
epidemiology, in native-born vs. foreign-born persons, Houston, 461
extrapulmonary, diagnosis, culture filtrate protein–10 and early secretory antigen target for, 175
in human immunodeficiency virus infection
CD88 expression and complement 5a–induced neutrophil response in, 662
chemokine activation in, 1801
cytokine profiles in, 1805
immune response, human leukocyte antigens in, 919
latent, epidemiology, urban India, 469

T cell response in, 779
treatment, monitoring, bactericidal assay for, 1300
Tumor necrosis factor–α
in bacterial meningitis, mouse model, 1749
in cryptococcosis, in human immunodeficiency virus infection, 294
in endotoxic shock, mouse model, 1617
human leukocyte antigen genes encoding, typhoid fever susceptibility and, 261
inhibition, chloroquine in, 935
in Lyme disease, mouse model, 1631
in malaria, in pregnancy, 1530
in meningococcal infection, effects of Toll-like receptor blockage on, 89
in *Mycobacterium avium* complex infection, 478
in sleeping sickness, 988
soluble receptor
in cryptococcosis, in human immunodeficiency virus infection, 294
in human immunodeficiency virus infection, virus load and, 1405
in *Trypanosoma brucei gambiense* infection, 988
in tuberculosis, 779, 919
with and without human immunodeficiency virus infection, 1805
Typhoid fever
major histocompatibility complex genes associated with, in Vietnam, 261
outbreaks, China, 1775
resistance to, natural resistance–associated macrophage protein 1 in, 1156
susceptibility to, human leukocyte antigens in, 261
vaccination, 1775

UL4 gene, cytomegalovirus, polymorphisms, in immunodeficiency, 218
UL97 gene, cytomegalovirus, mutations in, drug resistance and, 333
Ulcer(s)
aphthous, in human immunodeficiency virus infection, thalidomide for, 343
genital, in human immunodeficiency virus infection, virus load in, 1405
Treponema pallidum subtyping, Arizona, 1601
Urethritis, nongonococcal, organisms causing, 269
Urinary tract infections
catheter associated, S1
complicated, S1, S5, S66
diagnosis, S1
in elderly persons, S5
epidemiology, S1
Escherichia coli
ampicillin resistant, in pregnancy, 1526
phylogeny and virulence, dog model, 897
virulence factors, 1508
Escherichia coli O18:K1:H7, virulence factors, vs. neonatal meningitis, 425
etiology, S1
complicated, S5
genetic factors in, S66
historical background, S9
host defenses, S66
chemokine receptors, S61
defensins in, S41
fimbriae, S43, S47, S51, S84
interleukin-8 receptor, mouse model, S56
Toll-like receptor signaling, S61
inhibition, vaginal *Lactobacillus* in, in uropathogen adhesion inhibition, 485
microbiology, complicated, S5
overview, S1
pathogenesis *(see also subheading* microbiology; *specific organisms)*, S9
adhesins in, S24, S28
bacterial pili in, rodent model, S36
complicated, S5
glycosphingolipids in, S66
mouse model, S70
pathogenicity islands in, mouse model, S17, S32
secreted proteins in, mouse model, S32
virulence genes, S21
prevention, S1
carbohydrate receptor depletion in, mouse model, S70
current knowledge, S66
Escherichia coli vaccination in, mouse model, S84
hormone replacement in, S74
Lactobacillus in, S77
vaginal mucosal immunization in, S81
recurrent
prevention, S74
susceptibility to, S66
resistance in, S1
risk factors for, S1
septicemia in, hospitalization rate due to, in elderly persons, 596
severity, factors affecting, S61
streptococcal group B, in nursing homes, Maryland, 1138
susceptibility to, S66
in interleukin-8 receptor deficiency, mouse model, S56
treatment, S1, S9
bacterial outer membrane channels and, S12
vaccination, monkey and mouse models, S81
Urine, bacterial inhibitory factors in, S66

Vaccination
Ancylostoma ceylanicum, hamster model, 1380
cholera, misleading negative findings, 1306, 1308
cytomegalovirus
canarypox vector with phosphoprotein 65, 1171
guinea pig model, 59, 1547
diphtheria-tetanus toxoids, with subpotent diphtheria component, antitoxin levels in, 1698
Enterococcus faecalis, vaginal mucosal, S81
Escherichia coli
enterohemorrhagic, Shiga toxin 2 B subunit in, rabbit model, 435
genetically detoxified mucosal adjuvant with, mouse and pig models, 351
vaginal mucosal, S81
Haemophilus influenzae, in Cooley anemia, 1819
hookworm disease, hamster model, 1380
human immunodeficiency virus, 1343
canarypox vector for, 563
cohort for, disease characteristics in, 23
human papillomavirus, 8, 1485
influenza
in human immunodeficiency virus infection, 1000
methods for, 329
Klebsiella pneumoniae, vaginal mucosal, S81
measles, thymus damage by, mouse model, 498

meningococci
A/C conjugate, 5-year immunologic memory, 97
C conjugate, single dose, 160
with group B outer membrane protein, for sepsis, rabbit model, 1079
nasal, *Streptococcus mutans,* with cholera toxin adjuvant, mouse model, 823
parvovirus B19, 805
Plasmodium falciparum
circumsporozoite protein type, 640
monkey model, 303
pneumococcal
conjugate, serotypes 6A and 6B, mouse model, 253
epidemiologic studies for, United Kingdom, 239
intranasal, mouse model, 1494
poliomyelitis, disease outbreak after, 517
Proteus, vaginal mucosal, S81
respiratory syncytial virus, RNA vaccines for, mouse model, 1395
RNA, mouse model, 1395
schistosomiasis, chimpanzee model, 1238
sepsis, J5 *Escherichia coli* lipopolysaccharide/group B meningococcal outer membrane protein complex, rabbit model, 1079
tickborne encephalitis virus, RNA vaccines for, mouse model, 1395
typhoid fever, 1775
urinary tract infections, monkey and mouse models, S81
Vibrio cholerae, misleading negative findings, 1306, 1308
Vagina
candidiasis
drug resistance in, 286
in human immunodeficiency virus infection
immune response in, 277
treatment, virus shedding and, 1017
Lactobacillus in, in uropathogen adhesion inhibition, 485
microflora, condom use effects on, 913
secretory leukocyte protease inhibitor in, human immunodeficiency virus transmission and, 653
trichomoniasis, treatment, human immunodeficiency virus shedding and, 1017
Vaginosis, bacterial, cervical ectopy related to, in adolescent girls, 865
Valvular heart disease, rheumatic, pathogenesis, 507
Variant-specific surface proteins, *Giardia lamblia,* biological selection, mouse model, 119
Vascular cell adhesion molecule–1, in rheumatic carditis pathogenesis, 507
Vascular endothelial growth factor, in meningitis, 149
Vibrio cholerae
resistance to, 1701
vaccination, misleading negative findings, 1306, 1308
Viral Activation Transfusion Study, cytomegaloviremia in advanced human immunodeficiency virus infection, 1673
Virulence factors
Campylobacter jejuni, invasion antigens, 1607
Clostridium difficile, hamster model, 1760
Escherichia coli
ampicillin resistant, 1526
dog model, 897
extraintestinal, phylogenetic distribution, 78
ibeA brain microvascular endothelial cell invasion gene, 1071
nonenteropathogenic, 762
in urinary tract infections, S17, S21, S24, S28, S36, 1508
fimbriae, S43, S47, S51, S84
Escherichia coli O18:K1:H7, in cystitis vs. neonatal meningitis, 425
Helicobacter pylori, neutrophil-activating protein as, procoagulant action, 1055
Pseudomonas aeruginosa, 1767
Staphylococcus epidermidis, rat model, 1038
streptococci group A, mouse model, 1043
Visceral leishmaniasis, dog model, 1421
Vulvovaginal candidiasis, in human immunodeficiency virus infection, immune response in, 277

Waterborne infections, *Cryptosporidium parvum,* Milwaukee, 1373
Western blot test, for pneumococci, 1749
Whipple's disease, organism localization in, 1229

Yellow fever, hamster model, 1431, 1437

Zalcitabine, for human immunodeficiency virus infection, resistance to, 1732
Zidovudine, for human immunodeficiency virus infection
in pediatric patients, 1116, 1540
primary, 1466
prophylactic, 707, 1540
residual virus burden, 1318
resistance to, 1688, 1732
in triple combination, 571